WO2001081361A1 - Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death - Google Patents
Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death Download PDFInfo
- Publication number
- WO2001081361A1 WO2001081361A1 PCT/US2001/011501 US0111501W WO0181361A1 WO 2001081361 A1 WO2001081361 A1 WO 2001081361A1 US 0111501 W US0111501 W US 0111501W WO 0181361 A1 WO0181361 A1 WO 0181361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protective
- figures
- protective sequence
- nucleic acid
- cell
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 411
- 238000000034 method Methods 0.000 title claims abstract description 247
- 201000010099 disease Diseases 0.000 title claims abstract description 209
- 208000035475 disorder Diseases 0.000 title claims abstract description 198
- 230000030833 cell death Effects 0.000 title claims abstract description 149
- 239000000203 mixture Substances 0.000 title abstract description 25
- 230000001681 protective effect Effects 0.000 claims abstract description 608
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 197
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 158
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 158
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 266
- 150000001875 compounds Chemical class 0.000 claims description 158
- 230000014509 gene expression Effects 0.000 claims description 129
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 97
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 81
- 230000001105 regulatory effect Effects 0.000 claims description 80
- 230000000694 effects Effects 0.000 claims description 77
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- 229920001184 polypeptide Polymers 0.000 claims description 56
- 238000012360 testing method Methods 0.000 claims description 55
- 210000001519 tissue Anatomy 0.000 claims description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 34
- 108090000994 Catalytic RNA Proteins 0.000 claims description 32
- 102000053642 Catalytic RNA Human genes 0.000 claims description 32
- 230000000692 anti-sense effect Effects 0.000 claims description 32
- 108091092562 ribozyme Proteins 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 230000001404 mediated effect Effects 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 20
- 210000002569 neuron Anatomy 0.000 claims description 20
- 108700019146 Transgenes Proteins 0.000 claims description 18
- 230000009261 transgenic effect Effects 0.000 claims description 18
- 210000000056 organ Anatomy 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 14
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 208000028867 ischemia Diseases 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 51
- 208000006011 Stroke Diseases 0.000 abstract description 25
- 230000034994 death Effects 0.000 abstract description 22
- 230000008569 process Effects 0.000 abstract description 20
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 208000025966 Neurological disease Diseases 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 344
- 108090000623 proteins and genes Proteins 0.000 description 295
- 102000004169 proteins and genes Human genes 0.000 description 119
- 235000018102 proteins Nutrition 0.000 description 110
- 230000027455 binding Effects 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 45
- 241001465754 Metazoa Species 0.000 description 43
- 108091034117 Oligonucleotide Proteins 0.000 description 42
- 238000003556 assay Methods 0.000 description 39
- 239000012634 fragment Substances 0.000 description 39
- 238000001514 detection method Methods 0.000 description 33
- 108020004999 messenger RNA Proteins 0.000 description 31
- 230000035772 mutation Effects 0.000 description 31
- 108700026244 Open Reading Frames Proteins 0.000 description 29
- 239000002299 complementary DNA Substances 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 208000024891 symptom Diseases 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 208000014674 injury Diseases 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 102000054765 polymorphisms of proteins Human genes 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 21
- 230000003993 interaction Effects 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 241000894007 species Species 0.000 description 20
- 108700028369 Alleles Proteins 0.000 description 19
- 125000000539 amino acid group Chemical group 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 19
- 230000006378 damage Effects 0.000 description 19
- 230000007423 decrease Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 108020001507 fusion proteins Proteins 0.000 description 19
- 102000037865 fusion proteins Human genes 0.000 description 19
- 206010010356 Congenital anomaly Diseases 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 17
- -1 but not limited to Chemical class 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 230000017074 necrotic cell death Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 206010028851 Necrosis Diseases 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 230000037361 pathway Effects 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- 238000007792 addition Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000013615 primer Substances 0.000 description 15
- 108010033276 Peptide Fragments Proteins 0.000 description 14
- 102000007079 Peptide Fragments Human genes 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 13
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 13
- 108020004511 Recombinant DNA Proteins 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108700008625 Reporter Genes Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000003184 complementary RNA Substances 0.000 description 9
- 230000009918 complex formation Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 108020005544 Antisense RNA Proteins 0.000 description 8
- 208000005189 Embolism Diseases 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 239000000074 antisense oligonucleotide Substances 0.000 description 8
- 238000012230 antisense oligonucleotides Methods 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 230000016273 neuron death Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108700024394 Exon Proteins 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 108091000054 Prion Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000006721 cell death pathway Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 5
- 102100039556 Galectin-4 Human genes 0.000 description 5
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 5
- 201000009906 Meningitis Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 231100000676 disease causative agent Toxicity 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 208000037906 ischaemic injury Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 230000036244 malformation Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 210000002346 musculoskeletal system Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010012218 Delirium Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 208000031169 hemorrhagic disease Diseases 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000010396 two-hybrid screening Methods 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 241000251131 Sphyrna Species 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 201000004810 Vascular dementia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 108091006088 activator proteins Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000003816 antisense DNA Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000005002 female reproductive tract Anatomy 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 210000004995 male reproductive system Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 201000010225 mixed cell type cancer Diseases 0.000 description 3
- 208000029638 mixed neoplasm Diseases 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 208000019180 nutritional disease Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 208000008423 pleurisy Diseases 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 208000007056 sickle cell anemia Diseases 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 208000004020 Brain Abscess Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100038782 Carbohydrate sulfotransferase 1 Human genes 0.000 description 2
- 101710158459 Carbohydrate sulfotransferase 1 Proteins 0.000 description 2
- 241000242722 Cestoda Species 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 206010010305 Confusional state Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014612 Encephalitis viral Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 101150009006 HIS3 gene Proteins 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 2
- 206010020915 Hypervitaminosis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 206010027201 Meningitis aseptic Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 206010028665 Myxoedema Diseases 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 208000019155 Radiation injury Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 206010043784 Thyroiditis subacute Diseases 0.000 description 2
- 241000242541 Trematoda Species 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000005744 arteriovenous malformation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 201000009950 chronic meningitis Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229950002454 lysergide Drugs 0.000 description 2
- 208000021810 malignant mixed neoplasm Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 208000003786 myxedema Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000478 neocortex Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 201000007497 subacute thyroiditis Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 208000005057 thyrotoxicosis Diseases 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- NXJOFTRBTBDSHB-UHFFFAOYSA-N (4-methyl-1,4-diazepane-1-carbothioyl)sulfanyl 4-methyl-1,4-diazepane-1-carbodithioate Chemical compound C1CN(C)CCCN1C(=S)SSC(=S)N1CCN(C)CCC1 NXJOFTRBTBDSHB-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- 101150096372 1.3 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- GIJXKZJWITVLHI-UHFFFAOYSA-N 3-(diphenylmethyl)oxy-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2OC(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 101150094949 APRT gene Proteins 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 241000700606 Acanthocephala Species 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108700016475 Acid Phosphatase Deficiency Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010068625 Acquired phimosis Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 208000017612 Acute Hemorrhagic Pancreatitis Diseases 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 208000005952 Amniotic Fluid Embolism Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010067010 Anaphylactoid syndrome of pregnancy Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000006179 Aortic Coarctation Diseases 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010068220 Aspartylglucosaminuria Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- 241001235574 Balantidium Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 206010004552 Bicuspid aortic valve Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000021130 Bilirubin encephalopathy Diseases 0.000 description 1
- 208000021657 Birth injury Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700686 Chaetognatha Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010009807 Coarctation of the aorta Diseases 0.000 description 1
- 102100036486 Cobalamin binding intrinsic factor Human genes 0.000 description 1
- 101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010011385 Cri-du-chat syndrome Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 241000985276 Cycliophora Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000000077 Cysticercosis Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011951 Decompression Sickness Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010059352 Desmoid tumour Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010014405 Electrocution Diseases 0.000 description 1
- 206010056351 Emphysematous cystitis Diseases 0.000 description 1
- 206010014567 Empty Sella Syndrome Diseases 0.000 description 1
- 208000032096 Encephalitic infection Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010062608 Endocarditis noninfective Diseases 0.000 description 1
- 206010051909 Endometrial atrophy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 206010056246 Eosinophilic cystitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010061846 Extradural abscess Diseases 0.000 description 1
- 206010015769 Extradural haematoma Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 208000007358 Galactocele Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 208000009796 Gangliosidoses Diseases 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 241001466054 Gastrotricha Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 241000159512 Geotrichum Species 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010019027 Haemothorax Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000006031 Hydrops Fetalis Diseases 0.000 description 1
- 206010020529 Hydrops foetalis Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 206010020877 Hypertrophic osteoarthropathy Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 201000005503 Hypoplastic left heart syndrome Diseases 0.000 description 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000001911 Idiopathic aplastic anemia Diseases 0.000 description 1
- 208000009995 Idiopathic pulmonary hemosiderosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000007924 IgA Deficiency Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 201000002772 Kwashiorkor Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000934126 Leptomyxida Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 208000024369 Libman-Sacks endocarditis Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058225 Lupus endocarditis Diseases 0.000 description 1
- 206010052315 Lymphatic obstruction Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 206010026712 Mallory-Weiss syndrome Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010026730 Mammary duct ectasia Diseases 0.000 description 1
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 208000036696 Microcytic anaemia Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000001804 Monosomy 5p Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 206010028193 Multiple endocrine neoplasia syndromes Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 241000224436 Naegleria Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 208000036576 Obstructive uropathy Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000026616 Ollier disease Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000006024 Osteochondromatosis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033603 Pancreatic atrophy Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000024216 Periapical disease Diseases 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 206010034487 Pericarditis constrictive Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 241000242594 Platyhelminthes Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 206010059344 Protein-losing gastroenteropathy Diseases 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000008640 Pulmonary Atresia Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000700141 Rotifera Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 description 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010066075 Sialometaplasia Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000011942 Slow Virus disease Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010041092 Small for dates baby Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000002152 Splenic rupture Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000000002 Subdural Empyema Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 241000248384 Tetrahymena thermophila Species 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 206010043780 Thyroiditis acute Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 206010044242 Toxic nodular goitre Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010054000 Type II hypersensitivity Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047073 Vascular fragility Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047697 Volvulus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010047842 Water soluble vitamin deficiencies Diseases 0.000 description 1
- 208000004143 Waterhouse-Friderichsen Syndrome Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 241000223673 Xylohypha Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000758405 Zoopagomycotina Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000010442 acute cervicitis Diseases 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 201000004171 acute endometritis Diseases 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 201000006498 acute thyroiditis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 206010001689 alkaptonuria Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940054058 antipsychotic thioxanthene derivative Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 208000021654 bicuspid aortic valve disease Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000005761 carcinoid heart disease Diseases 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 201000003505 cervical polyp Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 208000022077 chronic encephalitis Diseases 0.000 description 1
- 208000030373 chronic endometritis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000011490 co-immunoprecipitation assay Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000035623 congenital anemia Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 201000000833 congenital nongoitrous hypothyroidism 1 Diseases 0.000 description 1
- 208000016598 congestive splenomegaly Diseases 0.000 description 1
- 208000000839 constrictive pericarditis Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 201000006827 desmoid tumor Diseases 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000013154 diagnostic monitoring Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 150000008533 dibenzodiazepines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 201000000165 epidural abscess Diseases 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 201000006440 gangliosidosis Diseases 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 201000011580 granulomatous orchitis Diseases 0.000 description 1
- 208000020390 granulomatous prostatitis Diseases 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000007000 hereditary hyperbilirubinemia Diseases 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000022594 hypothyroidism due to TSH receptor mutations Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003585 interneuronal effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 201000007647 intestinal volvulus Diseases 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 208000006663 kernicterus Diseases 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 201000010758 lactocele Diseases 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000019617 lysosomal acid phosphatase deficiency Diseases 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000007261 marantic endocarditis Diseases 0.000 description 1
- 206010026820 marasmus Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000004840 megacolon Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 201000005895 multinodular goiter Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 201000006478 necrosis of pituitary Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000009783 necrotizing sialometaplasia Diseases 0.000 description 1
- 206010028976 neonatal thyrotoxicosis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 206010065988 nodular fasciitis Diseases 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 208000016135 nonbacterial thrombotic endocarditis Diseases 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 208000030346 palmar fibromatosis Diseases 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000009291 paraphimosis Diseases 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 208000003278 patent ductus arteriosus Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 206010034878 phimosis Diseases 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000004333 pleomorphic adenoma Diseases 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 208000022076 postinfectious encephalitis Diseases 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 201000007183 prothrombin deficiency Diseases 0.000 description 1
- 201000006081 pseudosarcomatous fibromatosis Diseases 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 201000003456 pulmonary hemosiderosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 208000030390 pulmonic stenosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000002694 regional anesthesia Methods 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000004441 taeniasis Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 206010056873 tertiary syphilis Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 208000012175 toxemia of pregnancy Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000005820 transferase reaction Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000016082 traumatic myositis ossificans Diseases 0.000 description 1
- 208000007340 tricuspid atresia Diseases 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000008026 type II hypersensitivity Effects 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death, including, but not limited to, neurological disorders such as stroke.
- Nucleic acids are described herein which, when introduced into a cell either predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced Such nucleic acids are referred to as "protective sequences".
- Protective sequences or their products are identified by their ability to prevent, delay, or rescue a cell, cells, tissues, organs, or organisms from dying. Protective sequences or their products are also identified via their ability to interact with other genes or gene products involved in conditions or disorders involving cell death.
- the invention further includes recombinant DNA molecules and cloning vectors comprising protective sequences, and host cells and host organisms engineered to contain such DNA molecules and cloning vectors.
- the present invention further relates to protective sequence products and to antibodies directed against such protective sequence products.
- the protective sequences identified, their products, or antibodies may be used diagnostically, prophylactically, therapeutically or as targets for therapeutic intervention.
- the present invention provides methods for the identification and prophylactic or therapeutic use of compounds in the treatment and diagnosis of conditions, disorders, or diseases involving cell death. Additionally, methods are provided for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of conditions or disorders involving cell death, for monitoring the efficacy of compounds in clinical trials and for identifying subjects who may be predisposed to such conditions, disorders, or diseases involving cell death.
- necrosis and apoptosis are distinct components of numerous conditions, disorders and disease states.
- necrosis plays an important physiologic role in signaling the presence of certain conditions.
- the dying cells release substances that activate the body's immune response in a local, and in some cases widespread, reaction to the necrosis-inducing condition. This response is important in, for example, bacterial infection.
- preventing, delaying, or rescuing cells from death would either alleviate the disease or allow more time for definitive treatment to be administered to the patient.
- An example of this situation is brain cell death caused by ischemic stroke: preventing, delaying, or rescuing cells from death until the blood supply to the brain could be restored would greatly reduce, if not eliminate, the possibility of a person's death and/or long-term disability from stroke (Lee JM, et al. Nature 1999, 399(supp): A7-A14; Tarkowski E, et al. Stroke 1999, 30(2): 321-7; Pulera
- One method for regulating cell death involves manipulating the threshold at which the process of cell death begins. This threshold varies significantly by cell type, tissue type, the type of injury or insult suffered by the cell, cellular maturity, and the physiologic conditions in the cell's environment (Steller H, Science 1995, 267(5203): 1445-9). Although it is probable that certain cellular injuries or insults irrevocably induce death, lesser injuries or insults may begin the dying process without inducing irreversible cell death. What constitutes a lesser injury or insult may vary tremendously with changes in the factors influencing that cell's death threshold.
- bcl-2 is believed to regulate apoptotic death in neurons, kidney, heart, liver, blood and skin cells under experimental conditions. In addition to regulating death by apoptosis, bcl-2 is believed to regulate death caused by non-apoptotic mechanisms. Factors related to bcl-2 have been shown to be over-expressed in cancer and autoimmune conditions, disorders, or diseases (US Patent 5,856,171 and references cited therein). Other related factors acting on the same pathway as bcl-2 also delay or prevent cell death.
- bcl-2 prevented cell death in a brain ischemia model (Guegan C, et al. Neurobiol Dis 1999, 6(3): 180-9; Linnik MD, et al. Stroke 1995, 26(9): 1670-4). It was shown that the activity of bcl-2 to prevent neuronal death was consistently demonstrated across several different physiologic insults. It also has been demonstrated that the distinction between apoptotic death and necrotic death is open to question, so the possibility exists that bcl-2 can prevent or delay the necrotic cell death pathway, the apoptotic cell death pathway or perhaps an as yet undemonstrated cell death pathway. Preventing cell death is an important medical goal.
- delaying and/or rescuing cells from programmed cell death is also an important medical goal.
- delaying cell death would allow the pathological condition to be treated without permanent damage to the cells.
- the cells may be put into a suspended state from which they could successfully be rescued and emerge with their normal function intact.
- the present invention relates to the discovery, identification and characterization of protective sequences and to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death.
- Protective sequences refer to nucleic acid molecules comprising nucleic acid sequences which, when introduced into a cell either predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced.
- protective sequences may act to prevent, delay, ameliorate, inhibit, reduce, or rescue neuronal cell death (e.g. apoptosis, necrosis and related cellular events).
- the invention further relates to the discovery, identification and characterization of gene products encoded by such nucleic acid molecules, or by degenerate, e.g., allelic or homologous, variants thereof.
- Protective sequences also can be regulatory nucleic acids.
- Protective sequences further can be both coding sequences and regulatory sequences.
- Target sequences include, but are not limited to, upstream and downstream regulatory sequences, upstream and downstream complete or partial gene or gene product sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences and protective sequence products.
- Protective sequences and protective sequence products can be utilized prophylactically and/or therapeutically to prevent, delay ameliorate, inhibit, reduce, or rescue conditions of cell death or symptoms of conditions, disorders, or diseases involving cell death.
- the modulation of the expression of protective sequences, e.g., endogenous protective sequences, and/or the activity of the protective sequence products, e.g., endogenous protective sequence products, can also be utilized prophylactically or therapeutically to prevent, delay, ameliorate, inhibit, reduce, or rescue conditions of cell death or symptoms of conditions, disorders, or diseases involving cell death. Further, protective sequences and protective sequence products can be used to diagnose individuals exhibiting or predisposed to such conditions, disorders, or diseases involving cell death.
- compositions of the present invention include, in particular, nucleic acid molecules which comprise the following sequences: (a) nucleic acids of protective sequences, as well as allelic variants, homologs, mutants and fragments thereof; (b) nucleic acids which encode protective sequence products; (c) nucleic acids which encode protective sequence regulatory elements; (d) nucleic acids which encode fusion proteins comprising protective sequence products or one or more protective sequence product domains fused to a heterologous polypeptide; (e) nucleic acids which encode fusion proteins comprising protective sequence regulatory elements fused to a heterologous polypeptide; (f) nucleic acids which hybridize to the above described sequences under highly stringent or moderately stringent conditions, including, but not limited to, human homologs; and (g) complementary (e.g., antisense) nucleic acids of the sequences described in (a) through (f), above.
- the nucleic acid molecules of the invention include, but are not limited to, cDNA, genomic DNA and RNA sequences.
- the present invention also encompasses expression gene products of the protective sequences listed above; i.e., proteins and/or polypeptides that are encoded by the above protective sequences.
- the present invention also encompasses expression gene products generated by differentially or alternately splicing the protective sequences listed above. Nucleic acid molecules that can separately encode these differentially or alternatively spliced gene products are also included in the invention.
- Mimics, agonists and antagonists of the protective sequences, protective sequence products, genes, gene products, or their regulatory elements are also included in the present invention.
- Such mimics, agonists and antagonists will include, for example, small molecules, large molecules (e.g. , protective sequence product fragments or protective sequence product ligands) and antibodies directed against a protective sequence product.
- Mimics, agonists and antagonists of the invention also include nucleic acids, such as antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs, which can be used to modulate, inhibit or enhance expression of a protective sequence.
- the present invention further encompasses cloning and expression vectors, which may include, but are not limited to, bacterial, fungal, insect, plant, and mammalian vectors, which contain the protective nucleic acid sequences of the invention, which can be used as probes or to express those protective nucleic acid sequences, protective sequence products, genes and or gene products in host cells or organisms.
- the present invention also relates to cells that have been transformed, transfected, or infected with such vectors, and to cells engineered to contain or express the protective nucleic acid sequences, protective sequence products, genes, gene products, and/or regulatory elements of the invention.
- non-human host organisms which have been transformed, transfected, or infected with these protective nucleic acid sequences, or their regulatory elements, are also encompassed in the present invention.
- Host organisms of the invention include organisms transformed, transfected, or infected with the cloning vectors described above, including, but not limited to, non-human transgenic animals, and particularly transgenic non-human mammals which have been engineered to express a protective sequence, protective sequence product, gene, gene product, or regulatory element of the invention, or "knock-outs" which have been engineered to not express the protective sequence, protective sequence product, gene, gene product, or regulatory element of the invention.
- the transgenic animals of the invention include animals which express a mutant variant or polymorphism of a protective sequence, protective sequence product, gene, gene product, or regulatory element, particularly a mutant variant or polymorphism of a protective sequence, protective sequence product, gene, gene product, or regulatory element which is associated with a condition, disorder, or disease involving cell death.
- the transgenic animals of the invention further include those that express a protective sequence transgene at higher or lower levels than normal.
- the transgenic animals of the invention further include those which express the protective sequence, protective sequence product, gene, gene product, or regulatory element in all their cells, "mosaic” animals which express the protective sequence, protective sequence product, gene, gene product, or regulatory element in only some of their cells, and those in which the protective sequence, protective sequence product, gene, gene product, or regulatory element is selectively introduced into and expressed in a specific cell type(s).
- the transgenic animals of the invention also include "knock-out" animals. Knock-out animals comprise animals that have been engineered to no longer express the protective sequence, protective sequence product, gene, gene product, or regulatory element.
- the present invention also relates to methods and compositions for the diagnosis of conditions, disorders, or diseases involving cell death, as well as for the identification of subjects susceptible to such conditions, disorders, or diseases.
- Such methods comprise, for example, measuring expression of the protective sequence, protective sequence product, gene, gene product, or regulatory element in a patient sample, or detecting a mutation in the protective sequence, protective sequence product, gene, gene product, or regulatory element in the genome of a mammal, including a human, suspected of exhibiting such a condition, disorder, or disease.
- the protective nucleic acid molecules of the invention can be used also as diagnostic hybridization probes, or as primers for diagnostic PCR analysis to identify protective sequences, protective sequence products, genes, gene products, or regulatory element mutations, allelic variations or regulatory defects, such as defects in the expression of the protective sequence, protective sequence product, gene, gene product, or regulatory element.
- diagnostic PCR analyses can be used to diagnose individuals with a condition, disorder, or disease involving cell death associated with a particular protective sequence, protective sequence product, gene, gene product, or regulatory element mutation, allelic variation or regulatory defect.
- Such diagnostic PCR analyses can be used also to identify individuals susceptible to such conditions, disorders, or diseases involving cell death.
- compositions for the treatment of conditions, disorders, or diseases involving cell death also are included in the invention.
- Such methods and compositions can increase, decrease or otherwise modulate the level of protective sequences, protective sequence products, genes, gene products, or their regulatory elements in a patient in need of such treatment.
- Such methods and compositions can also modulate the level of protective sequence expression (e.g., endogenous protective sequence expression) and/or the level of activity of a protective sequence product, (e.g., endogenous protective sequence product).
- such methods include, for example, modulating the expression of the protective sequence and/or the activity of the protective sequence product for the treatment of conditions, disorders, or diseases involving cell death which are normally mediated by some other gene.
- such methods and compositions are utilized for the treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system including neurological and psychiatric conditions, disorders, or diseases; those of the peripheral nervous system; conditions, disorders, or diseases caused by physical injury; conditions, disorders, or diseases of the blood vessels or heart; conditions, disorders, or diseases of the respiratory system; neoplastic conditions, disorders, or diseases; conditions, disorders, or diseases of blood cells; conditions, disorders, or diseases of the gastrointestinal tract; conditions, disorders, or diseases of the liver; conditions, disorders, or diseases of the pancreas; conditions, disorders, or diseases of the kidney; conditions, disorders, or diseases of the ureters, urethra or bladder; conditions, disorders, or diseases of the male genital system; conditions, disorders, or diseases of the female genital tract; conditions, disorders, or diseases of the breast; conditions, disorders, or diseases of the endocrine system; conditions, disorders, or diseases
- the methods and compositions of the invention are utilized for the prevention, or delay, of cell death in the event of one or more infections which may be caused by bacteria; viruses; members of the family rickettsiae or chlamydia; fungi, yeast, hyphae or pseudohyphae; prions; protozoans; or metazoans.
- the compounds and methods of the invention can be used to treat infections or conditions, disorders, or diseases which cause cell death in organ systems including, but not limited to, blood vessels, heart, red blood cells, white blood cells, lymph nodes, spleen, respiratory system, oral cavity, gastrointestinal tract, liver and biliary tract, pancreas, kidney, lower urinary tract, upper urinary tract and bladder, male sexual organs and genitalia, female sexual organs and genitalia, breast, thyroid gland, adrenal gland, parathyroid gland, skin, musculoskeletal system, bone marrow or bones.
- organ systems including, but not limited to, blood vessels, heart, red blood cells, white blood cells, lymph nodes, spleen, respiratory system, oral cavity, gastrointestinal tract, liver and biliary tract, pancreas, kidney, lower urinary tract, upper urinary tract and bladder, male sexual organs and genitalia, female sexual organs and genitalia, breast, thyroid gland, adrenal gland, parathyroid gland, skin, musculoskeletal system,
- the compounds and methods of the invention can be used to treat further physiological impacts on organs caused by the infections which induce cell death including, but not limited to, fever equal to or greater than 101.5 degrees Fahrenheit, a decrease or increase in pulse rate by more than 20 beats per minute, a decrease or increase in supine systolic blood pressure by more than 30 millimeters of mercury, an increase or decrease in respiratory rate by more than 8 breaths per minute, an increase or decrease in blood pH by more than 0.10 pH units, an increase or decrease in one or more serum electrolytes outside of the clinical laboratory's usual reference range, an increase or decrease in the partial pressure of arterial oxygen or carbon dioxide outside of the clinical laboratory's usual reference range, an increase or decrease in white or red blood cells outside of the laboratory's usual reference range, an acute confusional state such as delirium where delirium is defined by the American Psychiatric Association's DSM-IV Manual or a diminished level of consciousness or attention.
- the compounds and methods of the invention can be used to promote cell death. These compounds could be useful for treating and/or ameliorating conditions caused by, for example, cancer and autoimmune diseases, both of which are manifested by an uncontrolled growth of cells.
- the invention still further relates to methods for identifying compounds which modulate the expression of a protective sequence and/or the synthesis or activity of a protective sequence product.
- Such compounds include therapeutic compounds which can be used as pharmaceutical compositions to reduce or eliminate the symptoms of conditions, disorders, or diseases involving cell death.
- Cellular and non-cellular assays are described which can be used to identify compounds which interact with a protective sequence, protective sequence product, gene, gene product, and/or regulatory element, e.g., modulate the activity of a protective sequence and/or bind to a protective sequence product.
- Such cell- based assays of the invention utilize cells, cell lines, or engineered cells or cell lines that express the protective sequence, protective sequence product, gene, gene product, and/or regulatory element.
- such methods comprise contacting a compound to a cell which expresses a protective sequence, protective sequence product, gene, gene product, and/or regulatory element, measuring the level of protective sequence expression, gene product expression or gene product activity, and comparing this level to the level of protective sequence expression, gene product expression or gene product activity produced by the cell in the absence of the compound, such that if the level obtained in the presence of the compound differs from that obtained in its absence, a compound which modulates the expression of the protective sequence and/or the synthesis or activity of protective sequence products has been identified.
- such methods comprise administering a compound to a host, e.g., a transgenic animal which expresses a protective sequence transgene or a mutant protective sequence transgene, and measuring the level of protective sequence expression, gene product expression or gene product activity.
- the measured level is compared to the level of protective sequence expression, gene product expression or gene product activity in a host which is not exposed to the compound, such that if the level obtained when the host is exposed to the compound differs from that obtained when the host is not exposed to the compound, a compound which modulates the expression of the protective sequence and/or the synthesis or activity of protective sequence products, and/or the symptoms of conditions, disorders, or diseases involving cell death, has been identified.
- Protective sequence refers to nucleic acid molecules comprising nucleic acid sequences which, when introduced into a cell predisposed to either undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous protective nucleic acids have been introduced.
- a protective sequence encodes a protective sequence product.
- protective sequences are any transcriptional products of the sequences disclosed herein.
- protective sequences comprise regulatory elements of the sequences disclosed herein which modulate the expression of a nucleic acid within a cell. For example, protective sequences, their products, or their regulatory elements may act to prevent, delay, or rescue a cell, cells, tissues, organs, or organisms from dying.
- protective sequence expression or activity of the protective sequence product can be used in the treatment of conditions, disorders or diseases associated with cell death processes. It is to be understood that the protective sequences described above can act to ameliorate or delay symptoms related to cell death. Although the protective sequences may be involved directly in such cell death related conditions or disorders, in certain cases, the protective sequences will not normally be involved in such conditions or disorders, but will be effective for the treatment and/or prevention of such disorders. In these cases, modulation of the expression of the protective sequence and/or the activity of the protective sequence product will be useful for the treatment of conditions, disorders, or diseases involving cell death which are normally mediated by some other gene.
- Cell death refers to any mechanism and/or pathway whereby a cell undergoes a series of events which ultimately would lead to the death of the cell.
- cell death may be caused by various processes including, but not limited to, apoptosis or programmed cell death, necrosis, or an as yet unidentified cell death pathway.
- Cell death may be induced in individual cells as a consequence of numerous internal and external stimuli including, but not limited to, genetic predisposition, toxic chemicals or processes, heat, cold, rapid environmental changes, radiation, viruses, prions, bacteria, disruption of nutrient balance, or exposure to bi-products and signaling from other cells undergoing cell death.
- the protective sequences disclosed herein, when introduced into a cell e.g. a neuronal cell
- a neuronal cell which has undergone an event that would ultimately lead to cell death
- ischemia e.g. ischemia
- a protective sequence in combination with a reporter gene (e.g. green fluorescent protein), is introduced into a cell which has undergone an event that would ultimately lead to cell death
- expression of the reporter gene is an indication that the protective sequence is capable of rescuing the cell from cell death.
- Protective nucleic acids See Table 1 for the identity, the sequence identifier number, the length in base pairs and the Accession Number for each of the sequences shown in these figures.
- Figure 2 Restriction map and diagram of plasmid pCMV-SPORT2. This plasmid was used as the clomng vector for the protective sequences. Each clone was ligated into the S ⁇ ll-Notl restriction sites of the plasmid.
- Figures 3A and 3B represent non-stroked, positive control samples.
- Figure 3C represents a positive control, stroked sample using Bcl-2.
- Figure 3D represents a stroked, negative control sample.
- Figure 3E represents a stroked sample protected by a representative protective sequence.
- Figure 3F presents the average number of neurons that survived for three days in both a stroked sample protected by a protective sequence and a corresponding stroked, negative control sample.
- compositions of the invention further include protective sequence products (e.g. proteins or RNA) which are encoded or produced by the nucleic acid molecules of the invention, and the modulation of protective sequence expression and/or gene product activity in the treatment of conditions, disorders, or diseases involving cell death.
- protective sequence products e.g. proteins or RNA
- antibodies directed against the protective sequence products, or conserved variants or fragments thereof, and viral-, cell-, plant-, and animal-based models by which the protective sequences may be further characterized and utilized are also discussed in this section.
- these protective sequences have been shown to prevent, delay, or rescue cell death in a cell predisposed for undergoing cell death, whether the pathway that leads to the cell death involves apoptosis, necrosis or an as yet undefined pathway.
- the protective sequences, their SEQ ID NOS and additional information related to the protective sequences are listed below, in Table 1.
- the protective sequences listed in Table 1 may be obtained using cloning methods well known to those skilled in the art, including but not limited to the use of appropriate probes to detect the protective sequences within an appropriate cDNA or gDNA (genomic DNA) library. (See, for example, Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, which is incorporated by reference herein in its entirety). Probes for the novel sequences reported herein may be obtained directly from CNI-NPP5-CP5, which represents a composite deposit containing the isolated clones, which was deposited with the ATCC as Accession No. 1491 on March 16, 2000. Accension number. Alternatively, oligonucleotide probes for the novel protective sequences may be synthesized based on the DNA sequences disclosed herein.
- the isolated protective nucleic acid molecules of the invention include, in particular, nucleic acid molecules which comprise the following sequences: (a) nucleic acids of protective sequences, as well as allelic variants, homologs, mutants and fragments thereof; (b) nucleic acids which encode protective sequence products and/or their regulatory elements, or fragments thereof; (c) nucleic acids which encode fusion proteins comprising protective sequence products and/or their regulatory elements, or one or more protective sequence product domains and/or their regulatory elements fused to a heterologous polypeptide; (d) nucleic acids which hybridize to the above described sequences under highly stringent or moderately stringent conditions, including, but not limited to human homologs; and (e) complementary (e.g., antisense) nucleic acids of the sequences described in (a) through (d), above.
- the nucleic acid molecules of the invention include, but are not limited to, cDNA, genomic DNA and RNA sequences.
- the nucleic acids of the invention also include nucleic acids which have at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more nucleic acid identity to the protective nucleic acids of (a)-(d) above.
- the nucleic acids of the invention further include nucleic acids which encode polypeptides having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or higher amino acid sequence identity to the polypeptides encoded by the protective nucleic acids of (a)-(d).
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).
- the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the two sequences are the same length.
- the determination of percent identity between two sequences also can be accomplished using a mathematical algorithm.
- a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:226A-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol.
- Gapped Gapped
- BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res.25: 3389-3402.
- PSI-Blast can be used to perform an iterated search that detects distant relationships between molecules (Id.).
- the default parameters of the respective programs e.g., XBLAST and NBLAST
- XBLAST and NBLAST can be used (see http://www.ncbi.nlm.nih.gov).
- Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) CABIOS 4:11-11.
- ALIGN program version 2.0
- a gap length penalty of 12 and a gap penalty of 4 can be used.
- the percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.
- the nucleic acids of the invention further include: (a) any nucleic acid which hybridizes to a nucleic acid molecule of the invention under moderately stringent conditions, e.g., hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65°C, or (b) under highly stringent conditions, e.g., hybridization to filter-bound nucleic acid in 6xSSC at about 45°C followed by one or more washes in O.lxSSC/0.2% SDS at about 68°C, or under other hybridization conditions which are apparent to those of skill in the art (see, for example,
- nucleic acid molecule that hybridizes to the nucleic acid of (a) and (b), above is one which comprises the complement of a nucleic acid molecule which encodes a protective sequence product.
- nucleic acid molecules comprising the nucleic acids of (a) and (b), above encode protective sequence products.
- Functionally equivalent protective sequence products include naturally occurring protective sequence products present in the same or different species. Functionally equivalent protective sequence products also include gene products which retain at least one of the biological activities of the protective sequence products, and/or which are recognized by and bind to antibodies (polyclonal or monoclonal) directed against the protective sequence products.
- oligos deoxyoligonucleotides
- Tm (°C) 81.5+16.6(log[monovalent cations (molar)])+0.41 (% G+C)-(500/N) where N is the length of the probe.
- Tm (°C) 81.5+16.6(log[monovalent cations (molar)])+0.41(% G+C)-(0.61% formamide)-(500/N) where N is the length of the probe.
- hybridization is carried out at about 20-25 degrees below Tm (for DNA- DNA hybrids) or 10-15 degrees below Tm (for RNA-DNA hybrids).
- Exemplary highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for about 14-base oligos), 48 °C (for about 17- base oligos), 55 °C (for about 20-base oligos) and 60 °C (for about 23-base oligos).
- Fragments of the nucleic acid molecules can be at least 10 nucleotides in length. Fragments of the nucleic acid molecules can refer also to exons or introns, and, further, can refer to portions of coding regions that encode domains of protective sequence products.
- the invention also encompasses (a) DNA vectors which contain any of the foregoing coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors which contain any of the foregoing coding sequences operatively associated with a regulatory element which directs the expression of the coding sequences; and (c) genetically engineered host cells which contain such vectors or have been engineered to contain and/or express a nucleic acid sequence of the invention, e.g., any of the foregoing coding sequences operatively associated with a regulatory element which directs the expression of the coding sequences in the host cell.
- regulatory elements include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art which drive and regulate expression.
- the invention further includes fragments of any of the DNA sequences disclosed herein.
- the nucleic acid molecules may encode or act as antisense molecules, useful, for example, in protective sequence regulation, and/or as hybridization probes and/or as primers in amplification reactions of protective nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for protective sequence regulation. Still further, such molecules may be used as components of diagnostic methods whereby, for example, the presence of a particular allele involved in a condition, disorder, or disease involving cell death may be detected.
- the protective nucleic acids of the invention can be readily obtained, for example, by standard sequencing and the sequences provided herein.
- DNA sequence polymorphisms of a protective sequence will exist within a population of individual organisms (e.g., within a human population). Such polymorphisms may exist, for example, among individuals within a population due to natural allelic variation. Such polymorphisms include ones that lead to changes in amino acid sequence.
- An allele is one of a group of alternative forms of a gene that occur at a given genetic locus.
- the phrase "allelic variant" refers to a nucleic acid that occurs at a given locus or to a gene product encoded by that nucleic acid.
- allelic variations can typically result in 1-5% variance in the nucleic acid of a given gene. Sequencing the gene of interest in a number of different individuals can identify alternative alleles. Using hybridization probes to identify the same genetic locus in a variety of individuals can readily carry this out.
- the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising any of up to six open reading frames which may or may not encode a polypeptide of the invention.
- the terms “gene” and “recombinant gene” refer to nucleic acid molecules encoding any of the open reading frames shown in Figures 4-13, and described in Tables 2-11, respectively.
- the term can further include nucleic acid molecules comprising upstream and/or exon/intron sequences and structures.
- Alternative or differential splicing of a gene that encodes any of the open reading frames shown in Figures 4-13 can also generate an alternative or differential protective sequence product.
- a gene that generates one of the protective sequence products shown in Figures 4-13 may be encoded by 4 out of 6 exons that comprise the entire gene; alternative or differential splicing of the gene can generate other protective sequence products that are encoded by 1, 2, 3, 4, 5, or 6 of the exons in the gene (Lewin, 2000, Genes VII, Oxford University Press, 702-705).
- the present invention also includes nucleic acid molecules comprising nucleic acids that separately encode these alternative or differential protective sequence products.
- the nucleic acid molecules comprise nucleic acids that encode an open reading frame of at least 3 contiguous amino acid residues from a full- length protein. In alternate embodiments, the nucleic acid molecules comprise an open reading frame which encodes at least about 5, 8, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or more contiguous amino acid residues of a protein.
- the sequence obtained from clones containing partial coding sequences or non-coding sequences can be used to obtain the entire coding region by using the RACE method, for example (Chenchik, et al., 1995, CLONTECHniques (X) 1: 5-8; Barnes, 1994, Proc. Natl. Acad. Sci. USA 91: 2216-2220; and Cheng et al, Proc. Natl. Acad. Sci. USA 91: 5695-5699).
- Oligonucleotides can be designed based on the sequence obtained from the partial clone that can amplify a reverse transcribed mRNA encoding the entire coding sequence.
- probes can be used to screen cDNA libraries prepared from an appropriate cell or cell line in which the protective sequence is transcribed.
- allelic variants of protective sequences associated with a condition, disorder, or disease involving cell death any and all such nucleotide variations and resulting amino acid polymorphisms or variations which are the result of natural allelic variation of the protective sequence are intended to be within the scope of the present invention.
- allelic variants include, but are not limited to, ones that do not alter the functional activity of the protective sequence product.
- the isolated protective sequences disclosed herein may be labeled and used to screen a cDNA library constructed from mRNA obtained from appropriate cells or tissues (e.g., brain) derived from the organism (e.g., guinea pig, cow and mouse) of interest.
- the hybridization conditions used generally should be of a lower stringency when the cDNA library is derived from an organism different from the type of organism from which the labeled sequence was derived, and can routinely be determined based on, e.g., relative relatedness of the target and reference organisms.
- the labeled fragment may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions.
- Appropriate stringency conditions are well known to those of skill in the art as discussed above, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions, see, for example, Sambrook, et al, 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y.; and Ausubel, et al, 1989-1999, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., both of which are incorporated herein by reference in their entirety.
- syntenic genes are genes which are believed to be located on the same chromosome because they are lost along with a marker gene which is known to be located on that chromosome.
- markers gene which is known to be located on that chromosome.
- a protective sequence allelic variant may be isolated from, for example, human nucleic acid, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the protective sequence product of interest.
- the template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines or tissue known or suspected to express a wild type or mutant protective sequence allele.
- the allelic variant is isolated from an individual who has a condition, disorder, or disease involving cell death. Such variants are described in the examples below.
- the PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a protective nucleic acid sequence.
- the PCR fragment may then be used to isolate a full-length cDNA clone by a variety of methods.
- the amplified fragment may be labeled and used to screen a bacteriophage cDNA library.
- the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.
- RNA may be isolated, following standard procedures, from an appropriate cellular or tissue source.
- a reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.
- the resulting RNA/DNA hybrid may then be "tailed" with guanines using a standard terminal transferase reaction.
- the hybrid may be digested with RNAase H and second strand synthesis may then be primed with a poly-C primer.
- cDNA sequences upstream of the amplified fragment may easily be isolated.
- the isolated protective sequence is the normal, or wild type gene
- this gene may be used to isolate mutant alleles of the protective sequence.
- Such an isolation is preferable in processes and disorders that are known or suspected to have a genetic basis.
- Mutant alleles may be isolated from individuals either known or suspected to have a genotype which contributes to symptoms of conditions, disorders, or diseases involving cell death. Mutant alleles and mutant allele products may then be utilized in the therapeutic and diagnostic assay systems described below.
- a cDNA of the mutant protective sequence may be isolated, for example, by using PCR, a technique well known to those of skill in the art.
- the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying the mutant allele, and by extending the new strand with reverse transcriptase.
- the second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal protective sequence.
- the product is then amplified via PCR, cloned into a suitable vector and subjected to DNA sequence analysis through methods well known to those of skill in the art.
- DNA sequence analysis By comparing the DNA sequence of the mutant protective sequence to that of the normal protective sequence, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be ascertained.
- a genomic or cDNA library can be constructed and screened using DNA or RNA, respectively, from a tissue known to or suspected of expressing the protective sequence of interest in an individual suspected of or known to carry the mutant allele.
- the normal protective sequence or any suitable fragment thereof may then be labeled and used as a probed to identify the corresponding mutant allele in the library.
- the clone containing this protective sequence may then be purified through methods routinely practiced in the art, and subjected to sequence analysis as described above in this Section.
- an expression library can be constructed utilizing DNA isolated from or cDNA synthesized from a tissue known to or suspected of expressing the protective sequence of interest in an individual suspected of or known to carry the mutant allele.
- protective sequence products made by the tissue containing the putative mutant alleles may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal protective sequence product, as described, below, in Section 5.3 (For screening techniques, see, for example, Hariow, E.
- the invention also includes nucleic acid molecules, preferably DNA molecules that are the complements of the nucleic acids of the preceding paragraphs.
- the protective nucleic acid molecules of the invention are present as part of protective nucleic acid molecules comprising nucleic acid sequences which do not contain heterologous (e.g., cloning vector or expression vector) sequences.
- the protective nucleic acid molecules of the invention further comprise vector sequences, e.g., cloning vectors or expression vectors.
- Protective sequence products or fragments thereof of the invention can be prepared for a variety of uses, including but not limited to, prophylactic or therapeutic modulators of protective sequence product function, for the generation of antibodies, diagnostic assays, or for the identification of other cellular or extracellular protective sequence products involved in the regulation of conditions, disorders, or diseases involving cell death.
- the protective sequence products of the invention include, but are not limited to, human protective sequence products and non-human protective sequence products, e.g., mammalian (such as bovine or guinea pig), protective sequence products.
- Protective sequence products of the invention includes those gene products encoded by any of up to six translational reading frames of the protective sequence sequences depicted in Table 1, as well as gene products encoded by other human allelic variants and non-human variants of protective sequence products which can be identified by the methods herein described.
- protective sequence product variants are protective sequence products comprising amino acid residues encoded by polymorphisms of such protective sequence products.
- protective sequence products of the invention may include proteins that represent functionally equivalent gene products.
- Functionally equivalent protective sequence products may include, for example, protective sequence products encoded by one of the nucleic acid molecules described in Section 5.1, above.
- Such functionally equivalent protective sequence products are naturally occurring gene products.
- Functionally equivalent protective sequence products also include gene products which retain at least one of the biological activities of the protective sequence products described above, and/or which are recognized by and bind to antibodies (polyclonal or monoclonal) directed against protective sequence products of the invention.
- Equivalent protective sequence products may contain deletions, including internal deletions, additions, including additions yielding fusion proteins, or substitutions of amino acid residues within and/or adjacent to the amino acid sequence encoded by the protective sequence sequences described, above, in Section 5.1.
- deletions will be deletions of single amino acid residues, or deletions of no more than about 2, 3, 4, 5, 10 or 20 amino acid residues, either contiguous or non-contiguous.
- additions or substitutions, other than additions which yield fusion proteins will be additions or substitutions of single amino acid residues, or additions or substitutions of no more than about 2, 3, 4, 5, 10 or 20 amino acid residues, either contiguous or non-contiguous.
- these modifications result in a "silent" change, in that the change produces a protective sequence product with the same activity as the original protective sequence product.
- nucleic acid changes resulting in amino acid additions or substitutions may also be made for the purpose of modifying the protective sequence product in order to generally enhance their use as therapeutic agents or components for assays, such modifications to include, but not be limited to, stabilizing the product against degradation, enhancing pharmacokinetic properties, modifying site tropisms at the level of cells, tissues, organs, or organisms.
- Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved.
- nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine; positively charged (basic) amino acids include arginine, lysine and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- non- natural amino acids including, but not limited to, D-amino acids may be used.
- addition(s), deletion(s) or non-conservative alterations can produce altered, including reduced-activity, protective sequence products.
- Such alterations can, for example, alter one or more of the biological functions of the protective sequence product.
- Such alterations can be selected so as to generate protective sequence products which include, but are not limited to, products which are better suited for expression, scale up, etc. in the host cells chosen.
- cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.
- Protective sequence products of the invention also include gene products generated by alternative or differential splicing patterns of a gene that encodes for the peptides shown in Figures 4-13.
- Protein fragments and/or peptides of the invention may comprise at least as many contiguous amino acid residues as necessary to represent an epitope fragment (that is to be recognized by an antibody directed to the protein). Examples of such protein fragments and/or peptides of the invention are shown by the open reading frames of the protective sequences shown in Figures 4-13, and described in Tables 2-11, respectively. In one nonlimiting embodiment of the invention, such protein fragments or peptides comprise at least about 3 contiguous amino acid residues from a full-length protein.
- the protein fragments and peptides of the invention can comprise about 5, 8, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or more contiguous amino acid residues of a protein.
- Peptides and/or proteins corresponding to one or more domains of the protein as well as fusion proteins in which a protein, or a portion of a protein such as a truncated protein or peptide or a protein domain, is fused to an unrelated protein are also within the scope of this invention.
- Such proteins and peptides can be designed on the basis of the nucleic acids disclosed in Section 5.1, above.
- Fusion proteins include, but are not limited to, IgFc fusions which stabilize the protein or peptide and prolong half -life in vivo; or fusions to any amino acid sequence which allows the fusion protein to be anchored to the cell membrane; or fusions to an enzyme, fluorescent protein, luminescent protein or a epitope tagged protein or peptide which provides a marker function.
- the protein sequences described above can include a domain, which comprises a protein transduction domain which targets the protective sequence product for delivery to various tissues and more particularly across the brain blood barrier, using, for example, the protein transduction domain of human immunodeficiency virus TAT protein (Schwarze et al, 1999, Science 285: 1569-72).
- a signal sequence includes a peptide of at least about 15 or 20 amino acid residues in length which occurs at the N-terminus of secretory and membrane-bound proteins and which contains at least about 70% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan or valine.
- a signal sequence contains at least about 10 to 40 amino acid residues, preferably about 19-34 amino acid residues and has at least about 60-80%, more preferably 65-75% and more preferably at least about 70% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a signal sequence of a polypeptide of the invention can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest.
- Signal sequences are typically characterized by a core of hydrophobic amino acids, which are generally cleaved from the mature protein during secretion in one or more cleavage events.
- Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway.
- the invention pertains to the described polypeptides having a signal sequence (that is, "immature" polypeptides), as well as to the signal sequences themselves and to the polypeptides in the absence of a signal sequence
- polypeptides of the invention can further comprise polypeptides comprising any signal sequence having characteristics as described above and a mature polypeptide sequence.
- a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate.
- the signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved.
- the protein can then be readily purified from the extracellular medium by art recognized methods.
- the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.
- proteins of the invention also include protein sequences wherein domains encoded by any transcriptional or post-transcriptional, and/or translational or post- translational modifications, or fragments thereof, have been deleted.
- the polypeptides of the invention can further comprise posttranslational modifications, including, but not limited to glycosylations, acetylations and myrisalations.
- the protective sequence products, peptide fragments thereof and fusion proteins thereof may be produced by recombinant DNA technology using techniques well known in the art.
- methods for preparing the protective sequence products, polypeptides, peptides, fusion peptide and fusion polypeptides of the invention by expressing nucleic acid containing protective sequence sequences are described herein.
- Methods that are well known to those skilled in the art can be used to construct expression vectors containing protective sequence product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo genetic recombination. See, for example, the techniques described in Sambrook, et al, 1989, supra, and Ausubel, et al., 1989, supra.
- RNA capable of encoding protective sequence product sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, ed., IRL Press, Oxford.
- host-expression vector systems may be utilized to express the protective sequence product coding sequences of the invention.
- Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the protective sequence product of the invention in situ.
- These include, but are not limited to, microorganisms such as bacteria (e.g., E. coli, B.
- subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing protective sequence product coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the protective sequence product coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculoviras) containing the protective sequence product coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMN; tobacco mosaic virus, TMN) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing protective sequence product coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g.,
- a number of expression vectors may be advantageously selected depending upon the use intended for the protective sequence product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of protective sequence product or for raising antibodies to protective sequence product, for example, vectors which direct the expression of high levels of fusion protein products which are readily purified may be desirable.
- vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al., 1983, ⁇ MBO J.
- pG ⁇ X vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transf erase (GST).
- GST glutathione S-transf erase
- fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
- the pG ⁇ X vectors are designed to include thrombin or factor
- Autographa californica, nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes.
- the virus grows in Spodoptera frugiperda cells.
- the protective sequence product coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of protective sequence product coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene).
- recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed, (e.g., see Smith, et al, 1983, J. Virol. 46:584; Smith, U.S. Patent No. 4,215,051).
- a number of viral-based expression systems may be utilized.
- the protective sequence product coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination.
- Insertion in a non-essential region of the viral genome will result in a recombinant virus that is viable and capable of expressing protective sequence products in infected hosts.
- a recombinant virus that is viable and capable of expressing protective sequence products in infected hosts.
- Specific initiation signals may also be required for efficient translation of inserted protective sequence product coding sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire protective sequence, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed.
- exogenous translational control signals including, perhaps, the ATG initiation codon
- the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
- exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner, et al., 1987, Methods in Enzymol. 153:516-544).
- a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.
- Different host cells have charac- teristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
- eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation and phosphorylation of the gene product may be used.
- Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3 and WI38.
- Additional host cells derived from neuronal tissue include, but are not limited to, PC-12 cells and primary dissociated neurons which are removed from the brain and grown in culture.
- stable expression is preferred.
- cell lines that stably express the protective sequence product may be engineered.
- host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
- engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
- the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
- This method may advantageously be used to engineer cell lines that express the protective sequence product.
- Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the protective sequence product.
- a number of selection systems may be used, including, but not limited to, the herpes simplex virus thymidine kinase (Wigler, et al, 1977, Cell 11:223), hypoxanthine- guanine phosphoribosyltransferase (Szybalska and Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al, 1980, Cell 22:817) genes can be employed in tk “ , hgprt " or aprt " cells, respectively.
- antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al, 1980, Proc. Natl. Acad. Sci. USA 77:3567; O ⁇ are, et al, 1981,
- DNA regulatory element into the genome of a stable cell line or cloned microorganism such that the inserted regulatory element is operatively linked with the endogenous protective sequence.
- an endogenous protective sequence which is normally "transcriptionally silent" i.e., a protective sequence which is normally not expressed, or is expressed only at very low levels in a cell line or microorganism, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed protective sequence product in that cell line or microorganism.
- a transcriptionally silent, endogenous protective sequence may be activated by insertion of a promiscuous regulatory element which works across cell types.
- the protective sequences may be associated operatively with a variety of different promoter/enhancer elements.
- the expression elements of these vectors may vary in their strength and specificities. Depending on the host/vector system utilized, any one of a number of suitable transcription and translation elements may be used.
- the promoter may be in the form of the promoter that is associated naturally with the gene of interest.
- the DNA may be positioned under the control of a recombinant or heterologous promoter, i.e., a promoter that is not associated normally with that gene.
- tissue specific promoter/enhancer elements may be used to regulate the expression of the transferred DNA in specific cell types.
- transcriptional control regions which exhibit tissue specificity which have been described and could be used, include, but are not limited to: choline acetyltransferase (ChAT) gene control region which is active in cholinergic cells in the brain (Lonnerberg et al, 1996, JBC 271:33358-65; Lonnerberg et al, 1995, PNAS 92: 4046-50; Ibenez and Perrson, 1991 Eur. J. Neurosci. 3: 1309-15), mouse Thy-1.2 gene control region which is active in adult neurons including hippocampus, thalamus, cerebellum, cortex, RGC, DRG, and MN in the brain (Caroni, 1997, J Neurosci. Meth.
- ChAT choline acetyltransferase
- NSE neuron specific enolase
- beta-globin gene control region which is active in myeloid cells
- myelin basic protein gene control region which is active in oligodendrocyte cells in the brain
- myosin light chain-2 gene control region which is active in skeletal muscle
- gonadotropic releasing hormone gene control region which is active in the hypothalamus
- Promoters isolated from the genome of viruses which grow in mammalian cells may be used, as well as promoters produced by recombinant DNA or synthetic techniques.
- promoters specifically activated within bone i.e., the osteocalcin promoter, which is specifically activated within cells of osteoblastic lineage, may be used to target expression of nucleic acids within bone cells.
- a heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with an endogenous protective sequence, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described e.g., in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991.
- fusion protein may readily purify any fusion protein.
- a system described by Janknecht, et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al, 1991, Proc. Natl. Acad. Sci. USA 88:8972-8976).
- the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues.
- Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ -nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.
- the protective sequence products can also be expressed in transgenic animals.
- transgenic refers to animals expressing protective sequences from a different species (e.g., mice expressing human protective sequences), as well as animals which have been genetically engineered to overexpress endogenous (i.e., same species) sequences or animals which have been genetically engineered to no longer express endogenous protective sequences (i.e., "knock-out" animals), and their progeny.
- Any technique known in the art may be used to introduce a protective sequence transgene into animals to produce the founder lines of transgenic animals.
- Such techniques include, but are not limited to, pronuclear microinjection (Hoppe and Wagner, 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al, 1985, Proc. Natl. Acad. Set, USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson, et al, 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol. Cell. Biol.
- transgenic animal clones containing a protective sequence transgene for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal or adult cells induced to quiescence (Campbell, et al, 1996, Nature 380:64-66; Wilmut, et al, Nature 385:810-813).
- the present invention provides for transgenic animals which carry a protective sequence transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals.
- the transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems.
- the transgene also may be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, et al, 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236).
- the regulatory sequences required for such a cell-type specific activation will depend on the particular cell type of interest, and will be apparent to those of skill in the art.
- gene targeting is preferred.
- vectors containing some nucleic acids homologous to the endogenous protective sequence are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleic acid of the endogenous protective sequence.
- the transgene also may be selectively introduced into a particular cell type, thus inactivating the endogenous protective sequence in only that cell type, by following, for example, the teaching of Gu, et al. (Gu, et al, 199 A, Science 265, 103-106).
- the regulatory sequences required for such a cell-type specific inactivation will depend on the particular cell type of interest, and will be apparent to those of skill in the art.
- the expression of the recombinant protective sequence may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis and RT-PCR (reverse transcriptase PCR). Samples of protective sequence-expressing tissue also may be evaluated immunocytochemically using antibodies specific for the transgene product.
- Protective proteins can be used, e.g., to treat cell death-related conditions, disorders, or diseases.
- Such protective sequence products include, but are not limited to, soluble derivatives such as peptides or polypeptides corresponding to one or more domains of the protective sequence product which are modified such that they are deleted for one or more hydrophobic domains.
- antibodies to the protein or anti-idiotypic antibodies which mimic the protective sequence product can be used to treat cell death-related conditions, disorders, or diseases involving the protective sequence product.
- nucleotide constructs encoding such protective sequence products can be used to genetically engineer host cells to express such protective sequence products in vivo; these genetically engineered cells can function as "bioreactors" in the body delivering a continuous supply of protective sequence product, peptides and soluble polypeptides.
- Described herein are methods for the production of antibodies capable of specifically recognizing one or more protective sequence product epitopes or epitopes of conserved variants or peptide fragments of the protective sequence products of the invention.
- antibodies that specifically recognize mutant forms of the protective sequence products of the invention are encompassed by the invention.
- the terms “specifically bind” and “specifically recognize” refer to antibodies which bind to protective sequence product epitopes involved in conditions, disorders, or diseases involving cell death at a higher affinity than they bind to protective sequence product epitopes not involved in such conditions, disorders, or diseases (e.g., random epitopes).
- Such antibodies may include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies and epitope-binding fragments of any of the above.
- mAbs monoclonal antibodies
- Such antibodies may be used, for example, in the detection of a protective sequence product in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal levels of protective sequence products, and/or for the presence of abnormal forms of such protective sequence products.
- Such antibodies also may be utilized in conjunction with, for example, compound screening schemes, as described, below, in Section 5.4.2, for the evaluation of the effect of test compounds on protective sequence product levels and/or activity. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described below, in Section 5.4.1.3., to evaluate, for example, the normal and/or engineered cells prior to their introduction into the patient.
- Antibodies derived from the protective sequence or protective sequence product including, but not limited to, antibodies and anti-idiotypic antibodies that mimic activity or function additionally may be used in methods for inhibiting abnormal protective sequence product activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods for protective sequence product-mediated conditions, disorders, or diseases.
- various host animals may be immunized with a protective sequence or protective sequence product, or a portion thereof.
- Such host animals may include, but are not limited to, rabbits, mice and rats, to name but a few.
- Various adjuvants may be used to increase the immunological response, depending on the host species, including, but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
- BCG Bacille Calmette-Guerin
- Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as protective sequence product, or an antigenic functional derivative thereof.
- an antigen such as protective sequence product, or an antigenic functional derivative thereof.
- host animals such as those described above, may be immunized with protective sequence product supplemented with adjuvants as also described above.
- Monoclonal antibodies which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Patent No.
- Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
- the hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.
- recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
- a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and
- Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule.
- CDRs complementarily determining regions
- Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No.
- Fully human antibodies are particularly desirable for therapeutic treatment of human patients.
- Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes.
- the transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention.
- Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology.
- the human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies.
- Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection.”
- a selected non- human monoclonal antibody e.g., a mouse antibody
- a completely human antibody recognizing the same epitope e.g., a completely human antibody recognizing the same epitope.
- a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al, U.S. Patent No. 4,816,567; and Boss et al, U.S. Patent No. 4,816397, which are incorporated herein by reference in their entirety.)
- An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarily determining regions (CDRs).
- CDRs complementarily determining regions
- the extent of the framework region and CDRs have been precisely defined (see, "Sequences of Proteins of Immunological Interest", Kabat, E. et al., U.S. Department of Health and Human Services (1983) ).
- humanized antibodies are antibody molecules from non-human species having one or more
- CDRs from the non-human species and a framework region from a human immunoglobulin molecule are CDRs from the non-human species and a framework region from a human immunoglobulin molecule.
- Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
- Antibody fragments that recognize specific epitopes may be generated by known techniques.
- such fragments include, but are not limited to: the F(ab') 2 fragments, which can be produced by pepsin digestion of the antibody molecule and the Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab') 2 fragments.
- Fab expression libraries may be constructed (Huse, et al, 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
- Described herein are various uses and applications of protective sequences, protective sequence products, including peptide fragments and fusion proteins thereof and of antibodies and anti-idiotypic antibodies derived from the protective sequence products and peptide fragments thereof.
- the application relates to compositions and methods for the treatment of conditions, disorders, or diseases involving cell death.
- Such applications include, but are not limited to, the prophylactic or therapeutic use of protective sequences which, when introduced into a cell predisposed to undergo cell death or in the process of dying, to prevent, delay, or rescue a cell, cells, tissue, organs, or organisms from dying, as described below in Section 5.4.1
- Such applications include methods for the treatment of conditions, disorders, or diseases involving cell death, including, but not limited to, those associated with the central nervous system including neurological and psychiatric conditions, disorders, or diseases, and others as described below, in Section 5.4.1.1, and for the identification of compounds which modulate the expression of the protective sequence and or the synthesis or activity of the protective sequence product, as described below, in Section 5.4.1.
- Such compounds can include, for example, other cellular products that are involved in such processes as the regulation of cell death. These compounds can be used, for example, in the amelioration of conditions, disorders, or diseases involving cell death.
- stroke which often is the result of ischemic injury.
- a relatively broad time window (8 hours to perhaps several days or longer) exists between the onset of ischemic injury (i.e. cessation or marked reduction in blood flow) before most neural cells actually die.
- These delayed biochemical intervention points represent ideal clinical intervention points as they correspond to the time period during which most stroke patients present for medical treatment.
- Many current medications for the treatment of stroke affect the physical and biochemical events that are acutely related to the initial onset of stroke, and, thus, must be administered soon after the biochemical cascades begin.
- vascular dementia multi-infarct dementia
- vascular dementia a repetitive process of small blood vessel diseases induces regional brain cell death, leading to a progressive loss of cognitive abilities.
- a partial list of other brain diseases which activate brain cell death pathways similar to those observed in stroke include, but are not limited to, Parkinson's disease, traumatic injury, Down's syndrome, Huntington's disease, HTV infection and intracranial infections.
- protective sequences include, but not limited to, prognostic and diagnostic evaluation of conditions, disorders, or diseases as described below in Section 5.4.1.1.
- methods can be employed for the diagnostic and prognostic evaluation of conditions, disorders, or diseases involving cell death and for the identification of subjects having a predisposition to such conditions, disorders, or diseases.
- methods of the invention include, for example, modulating the expression of the protective sequence and/or the activity of the protective sequence product for the treatment of conditions, disorders, or diseases involving cell death which are normally mediated by some other gene.
- diagnostic and prognostic methods may, for example, utilize reagents such as the protective nucleic acids described in Section 5.1, and antibodies directed against protective sequence products, including peptide fragments thereof, as described, above, in Section 5.3.
- reagents such as the protective nucleic acids described in Section 5.1, and antibodies directed against protective sequence products, including peptide fragments thereof, as described, above, in Section 5.3.
- such reagents may be used, for example, for: (1) the detection of the presence of protective sequence mutations, or the detection of either over- or under-expression of the protective sequence relative to wild-type levels of expression;
- Protective nucleic acids can, for example, be used to diagnose a condition, disorder, or disease involving cell death using, for example, the techniques for mutation/polymorphism detection described above in Section 5.1. Mutations at a number of different genetic loci may lead to phenotypes related to conditions, disorders, or diseases involving cell death. Ideally, the treatment of patients suffering from such conditions, disorders, or diseases will be designed to target the particular genetic loci containing the mutation mediating the condition, disorder, or disease. Genetic polymorphisms have been linked to differences in drug effectiveness. Thus, identification of alterations in protective sequence, protein or gene flanking regions can be utilized in pharmacogenetic methods to optimize therapeutic drug treatments.
- alterations i.e., polymorphisms, in the protective sequence or protein encoded by genes comprising such polymorphisms, are associated with a drug or drugs' efficacy, tolerance or toxicity, and may be used in pharmacogenomic methods to optimize therapeutic drug treatments, including therapeutic drug treatments for one of the conditions, disorders, or diseases described herein contained in Section 5.4.1.1, e.g., central nervous system conditions, disorders, or diseases.
- Such polymorphisms can be used, for example, to refine the design of drugs by decreasing the incidence of adverse events in drug tolerance studies, e.g., by identifying patient subpopulations of individuals who respond or do not respond to a particular drug therapy in efficacy studies, wherein the subpopulations have a polymorphism associated with drug responsiveness or unresponsiveness.
- the pharmacogenomic methods of the present invention also can provide tools to identify new drug targets for designing drugs and to optimize the use of already existing drugs, e.g., to increase the response rate to a drug and/or to identify and exclude non-responders from certain drug treatments (e.g., individuals having a particular polymorphism associated with unresponsiveness or inferior responsiveness to the drug treatment) or to decrease the undesirable side effects of certain drug treatments and/or to identify and exclude individuals with marked susceptibility to such side effects (e.g., individuals having a particular polymorphism associated with an undesirable side effect to the drug treatment).
- certain drug treatments e.g., individuals having a particular polymorphism associated with unresponsiveness or inferior responsiveness to the drug treatment
- to decrease the undesirable side effects of certain drug treatments e.g., individuals having a particular polymorphism associated with an undesirable side effect to the drug treatment.
- polymorphisms in the protective sequence or flanking this sequence, or variations in protective sequence expression, or activity may be utilized to identify an individual having a disease or condition resulting from a disorder involving cell death and thus define the most effective and safest drug treatment.
- Assays such as those described herein may be used to identify such polymorphisms or variations in protective sequence expression or activity.
- any nucleated cell can be used as a starting source for genomic nucleic acid.
- any cell type or tissue in which the protective sequence is expressed may be utilized. Nucleic acid-based detection techniques are described, below, in Section
- kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample i.e., a test sample.
- kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample i.e., a test sample.
- kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample i.e., a test sample.
- kits can be used, e.g., to determine if a subject is suffering from or is at increased risk of developing a condition, disorder, or disease associated with a disorder- causing allele, or aberrant expression or activity of a polypeptide of the invention.
- the kit can comprise a labeled compound or agent capable of detecting the polypeptide or mRNA or DNA or protective sequence sequences, e.g. , encoding the polypeptide in a biological sample.
- the kit can comprise further a means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody that binds the polypeptide or an oligonucleotide probe that binds to DNA or mRNA encoding the polypeptide).
- Kits can also include instructions for observing that the tested subject is suffering from, or is at risk of developing, a condition, disorder, or disease associated with aberrant expression of the polypeptide if the amount of the polypeptide or mRNA encoding the polypeptide is above or below a normal level, or if the DNA correlates with presence of an allele which causes a condition, disorder, or disease.
- the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or to the first antibody and is conjugated to a detectable agent.
- a first antibody e.g., attached to a solid support
- a second, different antibody which binds to either the polypeptide or to the first antibody and is conjugated to a detectable agent.
- the kit can comprise, for example: (1) an oligonucleotide (e.g., a detectably labeled oligonucleotide) which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention, or (2) a pair of primers useful for amplifying a nucleic acid molecule encoding a polypeptide of the invention.
- the kit also can comprise, for example, one or more buffering agents, preservatives or protein stabilizing agents.
- the kit also can comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate).
- the kit can contain also a control sample or a series of control samples that can be assayed and compared to the test sample.
- Each component of the kit usually is enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a condition, disorder, or disease associated with polymorphisms which correlate with alleles which cause conditions, disorders, or diseases involving cell death, and/or aberrant levels of mRNA, polypeptides or activity.
- the application relates to the compositions and methods for the development of screening assays for the identification of compounds, described in Section 5.4.2 below, which interact with or modulate protective sequences, protective sequence products, genes, gene products, and/or their regulatory elements.
- compositions and methods for the treatment of conditions, disorders, or diseases involving cell death include, but are not limited to, the prophylactic or therapeutic use of protective sequences, protective sequence products, genes, gene products, or the regulatory elements, target sequences, or variants of any of the aforementioned sequences or products, which, when introduced into a cell predisposed to undergo cell death or in the process of dying, prevent, delay, or rescue a cell, cells, tissue, organs, or organisms from dying.
- the application further relates to the methods and compositions whereby a condition, disorder, or disease involving cell death, including but not limited to, the conditions, disorders, or diseases mentioned in Section 5.4.1.1, may be treated wherein such methods can comprise administering antibodies, antisense molecules or sequences, ribozyme molecules, or other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, or the regulatory elements, target sequences, or variants of any of the aforementioned sequences or products.
- compositions and methods for those instances whereby the condition, disorder, or disease involving cell death results from protective sequence mutations can comprise supplying the subject with a nucleic acid molecule encoding an unimpaired protective sequence product such that an unimpaired protective sequence product is expressed and the cell, cells, tissue, organ, organism displaying symptoms of the condition, disorder, or disease is prevented, delayed, or rescued from death.
- such methods can comprise supplying the subject with a cell comprising a nucleic acid molecule which encodes an unimpaired protective sequence product such that the cell expresses the unimpaired protective sequence product and the cell, cells, tissue, organ, or organism displaying symptoms of the condition, disorder, or disease is prevented, delayed, or rescued from death.
- a loss of normal protective sequence product function results in the development of a condition, disorder, or disease involving cell death
- an increase in protective sequence product activity would facilitate progress towards an asymptomatic state in individuals exhibiting a deficient level of protective sequence expression and/or gene product activity.
- Methods for enhancing the expression or synthesis of protective sequence product can include, for example, methods such as those described below, in Section 5.4.1.3.
- symptoms of a condition, disorder, or disease involving cell death may be prevented, delayed, or rescued by administering a compound which decreases the level of protective sequence expression and/or gene product activity.
- Methods for inhibiting or reducing the level of protective sequence product synthesis or expression can include, for example, methods such as those described in Section 5.4.1.2.
- protective sequences are nucleic acid molecules comprising nucleic acid sequences which, when introduced into a cell predisposed to undergo cell death, prevent, delay, or rescue such cell death relative to a corresponding cell into which no exogenous protective sequence has been introduced.
- proteins and peptides which may be used in the methods of the invention include synthetic (e.g., recombinant or chemically synthesized) proteins and peptides, as well as naturally occurring proteins and peptides.
- the proteins and peptides may have both naturally occurring and non-naturally occurring amino acid residues (e.g., D-amino acid residues) and or one or more non-peptide bonds (e.g., imino, ester, hydrazide, semicarbazide, and azo bonds).
- the proteins or peptides may also contain additional chemical groups (i.e., functional groups) present at the amino and/or carboxy termini, such that, for example, the stability, bioavailability, and/or inhibitory activity of the peptide is enhanced.
- exemplary functional groups include hydrophobic groups (e.g. carbobenzoxyl, dansyl, and t- butyloxycarbonyl, groups), an acetyl group, a 9-fluorenylmethoxy-carbonyl group and macromolecular carrier groups (e.g., lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates) including peptide groups.
- Additional proteins and peptides which may be used in the methods of the invention include those described in WO 99/59615, which is herein incorporated by reference in its entirety.
- the types of conditions, disorders, or diseases which can be prevented, delayed, or rescued by the compounds and methods of the present invention include, but are not limited to, those associated with the central nervous system including neurological and psychiatric conditions, disorders, or diseases; those of the peripheral nervous system; conditions, disorders, or diseases caused by physical injury; conditions, disorders, or diseases of the blood vessels or heart; conditions, disorders, or diseases of the respiratory system; neoplastic conditions, disorders, or diseases; conditions, disorders, or diseases of blood cells; conditions, disorders, or diseases of the gastrointestinal tract; conditions, disorders, or diseases of the liver; conditions, disorders, or diseases of the pancreas; conditions, disorders, or diseases of the kidney; conditions, disorders, or diseases of the ureters, urethra or bladder; conditions, disorders, or diseases of the male genital system; conditions, disorders, or diseases of the female genital tract; conditions, disorders, or diseases of the breast; conditions, disorders, or diseases of the endocrine system; conditions, disorders, or diseases of the thymus or pineal
- Conditions, disorders, or diseases involving the central nervous system include, but are not limited to, common pathophysiologic complications such as increased intracraneal pressure and cerebral herniation, septic embolism, cerebral edema, suppurative endovasculitis and hydrocephalus; infections such as meningitis, acute meningitis, acute lymphocytic meningitis, chronic meningitis, purulent meningitis, syphilitic gumma, encephalitis, cerebral abscess, epidural abscess, subdural abscess, brain abscess, viral encephalitis, acute viral encephalitis, encephalomeningitis, aseptic meningitis, post-infectious encephalitis, subacute encephalitis, chronic encephalitis, chronic meningitis, chronic encephalomeningitis, slow virus diseases and unconventional agent encephalopathies; protozoal infections such as malaria, toxoplasmosis, amebias
- Conditions, disorders, or diseases caused by physical injury include, but are not limited to, the direct, indirect, immediate, or delayed effects of: changes in temperature such as frostbite and thermal bums; an increase in atmospheric pressure such as air blast or immersion blast caused by an explosion; a decrease in atmospheric pressure such as caisson disease or high-altitude hypoxia; mechanical violence from penetrating or non-penetrating traumatic injury; electromechanical energy such as radiation injury from either charged particles or electromagnetic waves; electrocution or non-ionizing radiation such as radio waves, microwaves, laser light or ultrasound.
- Conditions, disorders, or diseases of the blood vessels or heart include, but are not limited to, hypertension (high blood pressure), heart failure; ischemic or atherosclerotic heart disease; myocardial infarction; cardiac arrest; hypertensive heart disease; cor pulmonale; valvular heart disease such as that caused by rheumatic fever, aortic valve stenosis, mitral annulus calcification, carcinoid heart disease, nonbacterial thrombotic endocarditis, or nonbacterial verrucous endocarditis; infectious endocarditis caused by organisms including, but not limited to, Streptococcus species, Staphylococcus species, enterococci, pneumococci, gram-negative rods, Candida species, Aspergillus species, or culture-negative endocarditis; congenital heart disease such as atrial septal defect, ventricular septal defect, patent ductus arteriosis, coarctation of the aorta, Tetralogy of Fallot,
- Conditions, disorders, or diseases of the respiratory system include, but are not limited to, pulmonary congestion; heart failure; embolism; infarction; pulmonary hypertension; adult respiratory distress syndrome (ARDS); obstructive lung disease; restrictive lung disease; chronic obstructive pulmonary disease; asthma; sarcoidosis; diffuse interstitial or infiltrative lung diseases including, but not limited to, idiopathic pulmonary fibrosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, collagen-vascular diseases, or pulmonary eosinophilia; serofibrinous pleuritis; suppurative pleuritis; hemorrhagic pleuritis; pleural effusions; pneumothorax; hemothorax or pneumohemothorax.
- Neoplastic conditions, disorders, or diseases include, but are not limited to, benign tumors composed of one parenchymal cell type such as fibromas, myxomas, lipomas, hemangiomas, meningiomas, leiomyomas, adenomas, nevi, moles, or papillomas; benign mixed tumors derived from one germ layer such as a mixed tumor of salivary gland origin; benign mixed tumors derived from more than one germ layer such as a teratoma; primary malignant tumors or metastases of malignant tumors composed of one parenchymal cell type such as sarcomas, Ewing's tumor, leukemia, myeloma, histiocytosis X, Hodgkin's disease, lymphomas, carcinomas, melanomas, bronchial adenoma, small cell lung cancer, or seminoma; primary malignant tumors or metastases of mixed malignant tumors derived from one germ layer such as Wilms' tumor or malignant
- Conditions, disorders, or diseases of blood cells include, but are not limited to, anemia due to one or more of the following conditions: acute blood loss, chronic blood loss, hemolytic anemia, sickle cell disease, thalassemia syndromes, autoimmune hemolytic anemia, traumatic anemia, or diminished erythropoesis from megaloblastic anemia, iron deficiency, aplastic anemia, idiopathic bone marrow failure; polycythemia; hemorrhagic diatheses related to increased vascular fragility; hemorrhagic diatheses related to a reduction in platelets; idiopathic or thrombotic thrombocytopenic purpura; hemorrhagic diatheses related to defective platelet function; hemorrhagic diatheses related to abnormalities in clotting factor(s); disseminated intravascular coagulation (DIC); neutropenia; agranulocytosis; leukocytosis; plasma cell dyscrasias such as my
- Conditions,' disorders, or diseases of the gastrointestinal tract include, but are not limited to, congenital anomalies such as atresia, fistulas, or stenosis; periodontal disease; periapical disease; xerostomia; necrotizing sialometaplasia; esophageal rings or webs; hernia;
- Mallory- Weiss syndrome Mallory- Weiss syndrome; esophagitis; diverticulosis; diverticulitis; scleroderma; esophageal varices; acute or chronic gastritis; peptic ulcer; gastric erosion or ulceration; ischemic bowel disease; infarction; embolism; Crohn's disease; obstruction from foreign bodies, hernia, adhesion, intussusception, or volvulus; ileus; megacolon; angoidysplasia; ulcerative colitis; psuedomembranous colitis; or polyps.
- Conditions, disorders, or diseases of the liver include, but are not limited to, acute hepatic failure due to one of more of metabolic, circulatory, toxic, microbial, or neoplastic causes; chronic hepatic failure due to one or more of metabolic, circulatory, toxic, microbial, or neoplastic causes; hereditary hyperbilirubinemias; infarct; embolism; hepatic circulation thrombosis or obstruction; fulminant hepatic necrosis; portal hypertension; alcoholic liver disease; post-necrotic cirrhosis; biliary cirrhosis; cirrhosis associated with alpha- 1-antitrypsin deficiency; Wilson's disease; or Reye's syndrome.
- Conditions, disorders, or diseases of the pancreas include, but are not limited to, congenital aberrant pancreas, congenital anomalies of pancreatic ducts, stromal fatty infiltration, pancreatic atrophy, acute hemorrhagic pancreatitis, chronic pancreatitis, chronic calcifying pancreatitis, chronic obstructive pancreatitis, pancreatic psuedocyst, diabetes mellitus, or gestational diabetes.
- Conditions, disorders, or diseases of the kidney include, but are not limited to, congenital anomalies; polycystic renal disease; dialysis-associated cystic disease; glomerular disease, including, but not limited to, acute glomerulonephritis, acute proliferative glomerulonephritis, rapidly progressive glomerulonephritis, postinfectious rapidly progressive glomerulonephritis, Goodpasture's syndrome, idiopathic rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, lipoid nephrosis, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, focal proliferative glomerulonephritis, chronic glomerulonephritis, or hereditary nephritis; acute tubular necrosis; acute renal failure; tubulointerstitial diseases including, but not limited to, pyelonephritis
- Conditions, disorders, or diseases of the ureters, urethra or bladder include, but are not limited to, congenital anomalies; inflammatory diseases; physical obstruction by causes including, but not limited to calculi, strictures, neoplasia, blood clot, or pregnancy; sclerosing retroperitonitis; acute cystitis; chronic cystitis; interstitial cystitis; emphysematous cystitis; eosinophilic cystitis; encrusted cystitis; fistula; or neurogenic bladder.
- Conditions, disorders, or diseases of the male genital system include, but are not limited to, congenital anomalies; balanoposthitis; condyloma; phimosis; paraphimosis; dysplastic epithelial lesions; nonspecific epididymitis or orchitis; granulomatous orchitis; torsion of the testis or its vascular supply; granulomatous prostatitis; acute or chronic prostatitis; or benign prostatic hyperplasia.
- Conditions, disorders, or diseases of the female genital tract include, but are not limited to, congenital anomalies, lichen scleroses, acute cervicitis, chronic cervicitis, cervical polyps; acute endometritis; chronic endometritis; endometriosis; dysfunctional uterine bleeding; endometrial hyperplasia; senile cystic endometrial atrophy; salpingitis; polycystic ovary disease; pre-eclampsia or eclampsia (toxemia of pregnancy); placentitis; threatened abortion; or ectopic pregnancy.
- Conditions, disorders, or diseases of the breast include, but are not limited to, congenital anomalies, acute mastitis, chronic mastitis, galactocele, granulomas, traumatic fat necrosis, mammary duct ectasia, fibrocystic disease, sclerosing adenitis, epithelial hyperplasia, hypertrophy, or gynecomastia.
- Conditions, disorders, or diseases of the endocrine system include, but are not limited to, congenital anomalies; Sheehan's pituitary necrosis; empty sella syndrome; hyperthyroidism (thyrotoxicosis) from causes including, but not limited to, Graves' disease, toxic multinodular goiter, toxic adenoma, acute or subacute thyroiditis, TSH-secreting tumor, neonatal thyrotoxicosis, iatrogenic thyrotoxicosis; Hashimoto's thyroiditis; hypothyroidism (cretinism or myxedema) from causes including, but not limited to, surgical or radioactive ablation, primary idiopathic myxedema, iodine deficiency, goitrogenic agents, hypopituitarism, hypothalamic lesions, TSH resistance, subacute thyroiditis, or chronic thyroiditis; diffuse nontoxic simple or multinodular goiter; multiple endoc
- Conditions, disorders, or diseases of the skin or mucosa include, but are not limited to, melanocytic proliferative disorders; inflammatory dermatoses including, but not limited to, eczematous dermatitis, urticaria, erythema multiforme, cutaneous necrotizing vasculitis, cutaneous lupus erythematosus, graft-versus-host disease, panniculitis, acne vulgaris, rosacea, lichen planus, lichen sclerosus et atrophicus, pityriasis, psoriasis, or parapsoriasis; blistering diseases including, but not limited to, pemphigus, bullous pemphigoid, dermatitis herpetiformis, or porphyria.
- Conditions, disorders, or diseases of the musculoskeletal system include, but are not limited to, muscular atrophy; segmental necrosis; myositis; muscular dystrophy, including, but not limited to, Duchenne type, Becker type, Fascioscapulohumeral, Limb- Girdle, myotonic dystrophy, or ocular myopathy; congenital myopathies; myasthenia gravis; traumatic myositis ossificans; nodular fasciitis; desmoid tumors; palmar fibromatosis; congenital bone disorders including, but not limited to, osteogenesis imperfecta, achondroplasia, osteopetrosis, osteochondromatosis, endochondromatosis; osteomyelitis; fractures; osteoporosis; osteomalacia; bony changes secondary to hyperparathyroidism; Paget's disease; hypertrophic osteoarthropathy; fibrous dysplasia; or nonossifying fibroma.
- Conditions, disorders, or diseases causing a fluid or hemodynamic derangement include, but are not limited to, systemic edema; anasarca; edema from increased hydrostatic pressure including, but not limited to congestive heart ailure, cirrhosis of the liver, constrictive pericarditis, venous obstruction; edema from reduced oncotic pressure including, but not limited to, cirrhosis of the liver, malnutrition, protein-losing renal disease, protein-losing gastroenteropathy, protein loss through increased vascular permeability; edema from lymphatic obstruction including, but not limited to, cancer, inflammatory injury, surgical injury, traumatic injury, or radiation injury; edema from increased osmotic tension in the interstitial fluid including, but not limited to, sodium retention from excessive salt intake or increased renal sodium retention, reduced renal perfusion, acute or chronic renal failure, acute or chronic renal insufficiency; edema from increased endothelial permeability including, but not limited to, inflammation,
- disorders, or diseases include, but are not limited to, Down's syndrome, Edwards' syndrome, Patau's syndrome, other trisomies, Cri du Chat syndrome, Klinefelter's syndrome, XYY syndrome, Turner's syndrome, Multi-X female syndrome, hermaphrodism or pseudohermaphrodism, Marfan's syndrome, neurofibromatosis, vonHippel-Lindau disease, familial hypercholesterolemia, albinism, alkaptonuria, Fabry's disease, Fragile-X syndrome, Ehlers-Danlos syndromes, inherited neoplastic syndromes, inherited autosomal dominant conditions, Huntington's disease, Alport's disease, sickle-cell disease, thalessemia, tuberous sclerosis, vonWillebrand's disease, polycystic kidney disease, Pompe's disease, GMl-gangliosidosis; Tay-Sachs disease, Sandhoff-Jatzkewitz disease, metachromatic
- Conditions, disorders, or diseases of the immune system or spleen include, but are not limited to, Type I hypersensitivity conditions (anaphylaxis and other basophil or mast cell mediated conditions), Type II hypersensitivity conditions (cytotoxic conditions involving phagocytosis or lysis of target cell), Type Dl hypersensitivity conditions (immune complex conditions involving antigen-antibody complexes), Type JN hypersensitivity conditions (cell- mediated conditions), transplant rejection, systemic lupus erythematosus, Sjogren's syndrome, CREST, scleroderma, polymyositis-dermatomyositis, mixed connective tissue disease, polyarteritis nodosa, amyloidosis, X-linked agammaglobulinemia, common variable immunodeficiency, isolated IgA deficiency, Di George's syndrome, severe combined immunodeficiency, Wiscott-Aldrich syndrome, infection with HIV virus, acquired immune deficiency syndrome (AIDS), congenital anomalies
- Conditions, disorders, or diseases caused by a nutritional disease include, but are not limited to, marasmus, kwashiorkor, fat-soluble vitamin deficiency or toxicity (Vitamins A, D, E, or K), water-soluble vitamin deficiency or toxicity (thiamine, riboflavin, niacin, pyridoxine, folate, cobalamin, Vitamin C), mineral deficiency or toxicity (iron, calcium, magnesium, sodium, potassium, chloride, zinc, copper, iodine, cobalt, chromium, selenium, nickel, vanadium, manganese, molybdenum, rickets, osteomalacia, beriberi, hypoprothrombinemia, pellagra, megaloblastic anemia, scurvy, pernicious anemia, lack of gastric intrinsic factor, removal or pathophysiological functioning in the terminal ileum, microcytic anemia, or obesity.
- Conditions, disorders, or diseases typically occurring in infancy or childhood include, but are not limited to, preterm birth, congenital malformations from genetic causes, congenital malformations from infectious causes, congenital malformations from toxic or teratogenic causes, congenital malformations from radiation, congenital malformations from idiopathic causes, small for gestational age infants, perinatal trauma, perinatal asphyxia, perinatal ischemia or hypoxia, birth injury, intracranial hemorrhage, deformations, respiratory distress syndrome of the newborn, atelectasis, hemolytic disease of the newborn, kernicterus, hydrops fetalis, congenital anemia of the newborn, icterus gravis, phenylketonuria, galactosemia, cystic fibrosis, hamartoma, or choristoma.
- the compounds and methods of the invention can be used to treat infections that cause cell death.
- the infections may be caused by bacteria; viruses; members of the family rickettsiae or chlamydia; fungi, yeast, hyphae or pseudohyphae; prions; protozoas; or metazoas.
- aerobic or anaerobic bacteria which may cause such infections include, but are not limited to, gram-positive cocci, gram-positive bacilli (gram-positive rods), gram-negative cocci, gram-negative bacilli (gram-negative rods), Mycoplasma species,
- DNA, RNA or both DNA and RNA viruses which may cause such infections include, but are not limited to, members of the families adenoviridae, parvoviridae, papovaviridae, herpesviridae, poxviridae, picornaviridae, orthomyxoviridae, paramyxoviridae, rhabdoviridae, bunyaviridae, arenaviridae, coronaviridae, retroviridae, reoviridae, togaviridae and caliciviridae.
- Examples of members of the families rickettsiae or chlamydiae which may cause such infections include, but are not limited to, Rickettsia species, Rochalimaea species, Coxiella species or Chlamydia species.
- fungi examples include, but are not limited to, members of Ascomycota, Basidiomycota, Zygomycota, or Deutoeromycota (Fungi Imperfecti); Candida species, Cryptococcus species, Torulopsis species, Rhodotorula species, Sporothrix species, Phialophora species, Cladosporium species, Xylohypha species, Blastomyces species, Histoplasma species,
- Coccidioides species Paracoccidioides species, Geotrichum species, Aspergillus species, Rhizopus species, Mucor species, Pseudoallescheria species or Absidia species.
- prions which may cause such infections include, but are not limited to, the causative agent of Creutzfeldt- Jakob Disease, the causative agent of Gerstmann-Straussler-Scheinker Disease, the causative agent of fatal familial insomnia, the causative agent of kuru, and the causative agent of bovine spongiform encephalopathy.
- protozoa at any point in their life cycle which may cause such infections include, but are not limited to, Entamoeba species, Naegleria species, Acanthamoeba species, Pneumocystis species, Balantidium species, members of order Leptomyxida. Plasmodium species, Toxoplasma species, Leishmania species and Trypanosoma species.
- metazoa at any point in their life cycle which may cause such infections include, but are not limited to, members of Platyhelminthes such as the organisms in Cestoda (tapeworms) or Trematoda (flukes); or members of Aschelminthes such as the organisms in Acanthocephala, Chaetognatha, Cycliophora, Gastrotricha, Nematoda or Rotifera.
- members of Platyhelminthes such as the organisms in Cestoda (tapeworms) or Trematoda (flukes); or members of Aschelminthes such as the organisms in Acanthocephala, Chaetognatha, Cycliophora, Gastrotricha, Nematoda or Rotifera.
- the compounds and methods of the invention can be used to treat infections or disorders which cause cell death in organ systems including, but not limited to, blood vessels, heart, red blood cells, white blood cells, lymph nodes, spleen, respiratory system, oral cavity, gastrointestinal tract, liver and biliary tract, pancreas, kidney, lower urinary tract, upper urinary tract and bladder, male sexual organs and genitalia, female sexual organs and genitalia, breast, thyroid gland, adrenal gland, parathyroid gland, skin, musculoskeletal system, bone marrow or bones.
- the compounds and methods of the invention can be used to treat further physiological impacts on organs caused by the infections which induce cell death including, but not limited to, fever equal to or greater than 101.5 degrees
- the types of conditions, disorders, or diseases involving cell death which may be prevented, delayed, or rescued by modulating protective sequence expression, protective sequence product activity, or their regulatory elements by using protective sequences in conjunction with well-known antisense, gene "knock-out,” ribozyme and/or triple helix methods, are described.
- the compounds which may exhibit the ability to modulate the activity, expression or synthesis of the protective sequence, the protective sequence product, or its regulatory elements, including the ability to prevent, delay, or rescue a cell, cells, tissue, organ, or organism from the symptoms of a condition, disorder, or disease involving cell death are antisense, ribozyme and triple helix molecules.
- Such molecules may be designed to modulate, reduce or inhibit either unimpaired, or if appropriate, mutant protective sequence activity. Techniques for the production and use of such molecules are well known to those of skill in the art.
- Antisense RNA and DNA molecules act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation.
- Antisense approaches involve the design of oligonucleotides which are complementary to a protective sequence mRNA. The antisense oligonucleotides will bind to the complementary protective sequence mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required.
- a sequence "complementary" to a portion of an RNA means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed.
- the ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be).
- One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.
- oligonucleotides complementary to non-coding regions of the protective sequence of interest could be used in an antisense approach to inhibit translation of endogenous mRNA.
- Antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length.
- the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides. Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit protective sequence expression.
- these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the cerebral RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleic acid of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.
- the oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
- the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc.
- the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al, 1989, Proc. Natl. Acad. Sci. U.S.A.
- the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
- the antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil,
- D-mannosylqueosine 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6- isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil- 5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino- 3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.
- the antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.
- the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.
- the antisense oligonucleotide is an a-anomeric oligonucleotide.
- An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier, et al., 1987, Nucl. Acids Res. 15:6625-6641).
- the oligonucleotide is a 2'-0- methylribonucleotide (Inoue, et al, 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue, et al, 1987, FEBS Lett. 215:327-330).
- Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.).
- an automated DNA synthesizer such as are commercially available from Biosearch, Applied Biosystems, etc.
- phosphorothioate oligonucleotides may be synthesized by the method of Stein, et al (1988, Nucl. Acids Res. 16:3209)
- methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin, et al, 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc. While antisense nucleotides complementary to the protective sequence coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred.
- Antisense molecules should be delivered to cells that express the protective sequence in vivo.
- a number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies which specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.
- a preferred approach to achieve intracellular concentrations of the antisense sufficient to suppress translation of endogenous mRNAs utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol DJ or pol II promoter.
- a vector can be introduced e.g., such that it is taken up by a cell and directs the transcription of an antisense RNA.
- a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
- Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.
- Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3 '-long terminal repeat of Rous sarcoma virus (Yamamoto, et al, 1980, Cell 22:181-191), the herpes thymidine kinase promoter (Wagner, et al, 1981, Proc. Natl. Acad. Sci. U.S.A.
- plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA constract that can be introduced directly into the tissue site.
- viral vectors can be used that selectively infect the desired tissue, in which case administration may be accomplished by another route (e.g., systemically).
- Ribozyme molecules designed to catalytically cleave target gene mRNA transcripts can also be used to prevent translation of target gene mRNA and, therefore, expression of target gene product. (See, e.g. , PCT International Publication WO90/11364, published October 4, 1990; Sarver, et al, 1990, Science 247, 1222-1225).
- Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
- the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event.
- the composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see, e.g., U.S. Patent No. 5,093,246, which is incorporated herein by reference in its entirety.
- ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy target gene mRNAs
- the use of hammerhead ribozymes is preferred.
- Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions which form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The constraction and production of hammerhead ribozymes is well known in the art and is described more fully in Myers,
- the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the target gene mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.
- the ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes”) such as the one which occurs naturally in Tetrahymena thermophila (known as the JNS, or L-19 INS R ⁇ A) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al, 1984, Science, 224:574-578; Zaug and Cech,
- the Cech-type ribozymes have an eight base pair active site that hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place.
- the invention encompasses those Cech-type ribozymes that target eight base-pair active site sequences that are present in the target gene.
- the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells that express the target gene in vivo.
- a preferred method of delivery involves using a DNA constract "encoding" the ribozyme under the control of a strong constitutive pol HI or pol ⁇ promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous target gene messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.
- Endogenous target gene expression can also be reduced by inactivating or "knocking out" the target gene or its promoter using targeted homologous recombination
- a mutant, non-functional target gene flanked by DNA homologous to the endogenous target gene (either the coding regions or regulatory regions of the target gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells which express the target gene in vivo. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene.
- ES embryonic stem
- endogenous target gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the target gene
- Nucleic acid molecules to be used in triple helix formation for the inhibition of transcription should be single stranded and composed of deoxynucleotides.
- the base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizable stretches of either purines or pyrimidines to be present on one strand of a duplex.
- Nucleic acids may be pyrimidine-based, which will result in TAT and CGC + triplets across the three associated strands of the resulting triple helix.
- the pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand.
- nucleic acid molecules may be chosen which are purine-rich, for example, contain a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.
- the potential sequences that can be targeted for triple helix formation may be increased by creating a so-called "switchback" nucleic acid molecule.
- Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizable stretch of either purines or pyrimidines to be present on one strand of a duplex.
- the technique may so efficiently reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles which the possibility may arise wherein the concentration of normal target gene product present may be lower than is necessary for a normal phenotype.
- nucleic acid molecules which encode and express target gene polypeptides exhibiting normal target gene activity may, be introduced into cells via gene therapy methods such as those described, below, in Section 5.4.1.3 which do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized.
- the target gene encodes an extracellular protein, it may be preferable to co-administer normal target gene protein in order to maintain the requisite level of target gene activity.
- Anti-sense RNA and DNA, ribozyme, and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA molecules, as discussed above. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid-phase phosphoramidite chemical synthesis.
- RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
- antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.
- Protective nucleic acid sequences described above in Section 5.1, can be utilized for transferring recombinant protective nucleic acid sequences to cells and expressing said sequences in recipient cells. Such techniques can be used, for example, in marking cells or for the treatment of a condition, disorder, or disease involving cell death. Such treatment can be in the form of gene replacement therapy. Specifically, one or more copies of a normal protective sequence or a portion of the protective sequence which directs the production of a protective sequence product exhibiting normal protective sequence function, may be inserted into the appropriate cells within a patient, using vectors which include, but are not limited to adenovirus, adeno-associated virus and retroviras vectors, in addition to other particles which introduce DNA into cells, such as liposomes.
- vectors which include, but are not limited to adenovirus, adeno-associated virus and retroviras vectors, in addition to other particles which introduce DNA into cells, such as liposomes.
- the protective sequence of the invention may be expressed in the brain, such gene replacement therapy techniques should be capable of delivering protective sequences to these cell types within patients.
- techniques which are well known to those of skill in the art can be used to enable protective sequences to cross the blood-brain barrier readily and to deliver the sequences to cells in the brain.
- viral vectors such as, for example, those described above, are preferable.
- techniques for delivery involve direct administration, e.g., by stereotactic delivery of such protective sequences to the site of the cells in which the protective sequences are to be expressed.
- the nucleic acid is directly administered in vivo into a target cell or a transgenic mouse that expresses SP-10 promoter operably linked to a reporter gene.
- This can be accomplished by any methods known in the art, e.g. , by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see U.S. Patent No.
- microparticle bombardment e.g., a gene gun; Biolistic, Dupont
- lipids or cell-surface receptors or transfecting agents by encapsulation in liposomes, microparticles, or microcapsules, by administering it in linkage to a peptide which is known to enter the nucleus, or by administering it in linkage to a ligand subject to receptor- mediated endocytosis (see e.g., Wu and Wu, 1987, J. Biol. Chem.
- nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.
- the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180 dated April 16, 1992; WO 92/22635 dated December 23, 1992; WO92/20316 dated November 26, 1992; WO93/14188 dated July 22, 1993; WO 93/20221 dated October 14, 1993).
- Additional methods which may be utilized to increase the overall level of protective sequence expression and/or gene product activity include using targeted homologous recombination methods, discussed in Section 5.2, above, to modify the expression characteristics of an endogenous protective sequence in a cell or microorganism by inserting a heterologous DNA regulatory element such that the inserted regulatory element is operatively linked with the endogenous protective sequence in question.
- Targeted homologous recombination can thus be used to activate transcription of an endogenous protective sequence which is "transcriptionally silent", i.e., is not normally expressed or is normally expressed at very low levels, or to enhance the expression of an endogenous protective sequence which is normally expressed.
- the overall level of protective sequence expression and/or gene product activity may be increased by the introduction of appropriate protective sequence- expressing cells, preferably autologous cells, into a patient at positions and in numbers which are sufficient to ameliorate the symptoms of a condition, disorder, or disease involving cell death.
- appropriate protective sequence- expressing cells preferably autologous cells
- Such cells may be either recombinant or non-recombinant.
- cells that can be administered to increase the overall level of protective sequence expression in a patient are normal cells, preferably brain cells, which express the protective sequence.
- cells preferably autologous cells, can be engineered to express protective sequences, and may then be introduced into a patient in positions appropriate for the amelioration of the symptoms of a condition, disorder, or disease involving cell death.
- cells which express an unimpaired protective sequence and which are from a MHC matched individual can be utilized, and may include, for example, brain cells.
- the expression of the protective sequences is controlled by the appropriate gene regulatory sequences to allow such expression in the necessary cell types.
- gene regulatory sequences are well known to the skilled artisan.
- Such cell-based gene therapy techniques are well known to those skilled in the art, see, e.g., Anderson, U.S. Patent No. 5,399,349.
- the cells to be administered are non-autologous cells, they can be administered using well-known techniques that prevent a host immune response against the introduced cells from developing.
- the cells may be introduced in an encapsulated form that, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.
- compounds such as those identified via techniques such as those described, in Section 5.4.2, which are capable of modulating protective sequences, protective sequence product activity, or their regulatory sequences can be administered using standard techniques which are well known to those of skill in the art.
- the administration techniques should include well known methods that allow for a crossing of the blood-brain barrier.
- a variety of methods can be employed to screen for the presence of protective sequence-specific mutations or polymorphisms (including polymorphisms flanking protective sequences) and to detect and/or assay levels of protective nucleic acid sequences.
- Mutations or polymorphisms within or flanking the protective sequences can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard nucleic acid preparation procedures that are well known to those of skill in the art.
- Protective nucleic acid sequences may be used in hybridization or amplification assays of biological samples to detect abnormalities involving protective sequence structure, including point mutations, insertions, deletions, inversions, translocations and chromosomal rearrangements.
- assays may include, but are not limited to, Southern analyses, single-stranded conformational polymorphism analyses (SSCP) and PCR analyses.
- Diagnostic methods for the detection of protective sequence-specific mutations or polymorphisms can involve for example, contacting and incubating nucleic acids obtained from a sample, e.g., derived from a patient sample or other appropriate cellular source with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate variants thereof, such as described in Section 5.1, above, under conditions favorable for the specific annealing of these reagents to their complementary sequences within or flanking the protective sequence.
- the diagnostic methods of the present invention further encompass contacting and incubating nucleic acids for the detection of single nucleotide mutations or polymorphisms of the protective sequence.
- these nucleic acid reagent sequences within the protective sequence are 15 to 30 nucleotides in length.
- nucleic acid from the cell type or tissue of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads.
- a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads.
- non-annealed, labeled nucleic acid reagents of the type described in Section 5.1 are easily removed. Detection of the remaining, annealed, labeled nucleic acid reagents is accomplished using standard techniques well known to those skilled in the art.
- the protective sequences of the invention to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal protective sequence of the invention in order to determine whether a protective sequence mutation is present.
- protective sequence mutations or polymorphisms can be detected by using a microassay of nucleic acid sequences of the invention immobilized to a substrate or "gene chip" (see, e.g. Cronin, et al., 1996, Human Mutation 7:244-255).
- Alternative diagnostic methods for the detection of protective sequence-specific nucleic acid molecules (or flanking sequences), in patient samples or other appropriate cell sources may involve their amplification, e.g., by PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), followed by the analysis of the amplified molecules using techniques well known to those of skill in the art, such as, for example, those listed above.
- the resulting amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of the protective sequence in order to determine whether a protective sequence mutation or polymorphism in linkage disequilibrium with a disease-causing allele exists.
- oligonucleotide primers that amplify exon sequences.
- the sequences of such oligonucleotide primers are, therefore, preferably derived from cerebral intron sequences so that the entire exon, or coding region, can be analyzed as discussed below.
- Primer pairs useful for amplification of cerebral exons are preferably derived from adjacent introns. Appropriate primer pairs can be chosen such that each of the cerebral exons present within the gene will be amplified. Primers for the amplification of exons can be routinely designed by one of ordinary skill.
- nucleic acid sequences which are preferred for such amplification- related analyses are those which will detect the presence of a polymorphism which differs from the sequence depicted in the Figures.
- polymorphisms include ones that represent mutations associated with a condition, disorder, or disease involving cell death.
- Amplification techniques are well known to those of skill in the art and can routinely be utilized in connection with primers such as those described above.
- well-known genotyping techniques can be performed to identify individuals carrying protective sequence mutations. Such techniques include, for example, the use of restriction fragment length polymorphisms (RFLPs), which involve sequence variations in one of the recognition sites for the specific restriction enzyme used.
- RFLPs restriction fragment length polymorphisms
- Markers which are so closely spaced exhibit a high frequency of co-inheritance, and are extremely useful in the identification of genetic mutations, such as, for example, mutations within the protective sequence of the invention, and the diagnosis of diseases and disorders related to mutations of the protective sequences of the invention.
- Caskey et al. (U.S. Pat.No. 5,364,759) describe a DNA profiling assay for detecting short tri- and tetra nucleotide repeat sequences. The process includes extracting the DNA of interest, amplifying the extracted DNA and labeling the repeat sequences to form a genotypic map of the individual's DNA.
- SNPs single nucleotide polymorphisms
- biallelic SNPs or biallelic markers which have two alleles, both of which are present at a fairly high frequency in a population.
- Conventional techniques for detecting SNPs include, e.g., conventional dot blot analysis, single stranded conformational polymorphism (SSCP) analysis (see, e.g., Orita et al, 1989, Proc. Natl. Acad. Sci.
- SSCP single stranded conformational polymorphism
- DGGE denaturing gradient gel electrophoresis
- heteroduplex analysis mismatch cleavage detection and other routine techniques well known in the art (see, e.g., Sheffield et al, 1989, Proc. Natl. Acad. Sci. 56:5855-5892; Grompe, 1993, Nature Genetics 5: 111-117).
- preferred methods of detecting and mapping SNPs involve microsequencing techniques wherein an SNP site in a target DNA is detecting by a single nucleotide primer extension reaction (see, e.g., Goelet et al, PCT Publication No. WO92/15712; Mundy, U.S. Patent No.
- RNA from a cell type or tissue known, or suspected, to express the protective sequence, such as brain may be isolated and tested utilizing hybridization or PCR techniques such as are described, above.
- the isolated cells can be derived from cell culture or from a patient.
- the analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the protective sequence.
- analyses may reveal both quantitative and qualitative aspects of the expression pattern of the protective sequence, including activation or inactivation of protective sequence expression.
- a cDNA molecule is synthesized from an RNA molecule of interest (e.g. , by reverse transcription of the RNA molecule into cDNA).
- a sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like.
- the nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method are chosen from among the protective sequence nucleic acid reagents described in Section 5.1.
- the preferred lengths of such nucleic acid reagents are at least 9-30 nucleotides.
- the nucleic acid amplification may be performed using radioactively or non- radioactively labeled nucleotides.
- enough amplified product may be made such that the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.
- Nucleic acid reagents such as those described in Section 5.1 may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G.J., 1992, “PCR hi Situ Hybridization: Protocols And Applications", Raven Press, NY).
- Standard Northern blot analysis can be performed to determine the level of mRNA expression of the protective sequence.
- Protective sequence products of the invention including both wild-type and mutant protective sequence products, conserved variants and polypeptide fragments thereof, which are discussed, above, in Section 5.2, may be detected using antibodies which are directed against such gene products. Such antibodies, which are discussed in Section 5.3, above, may thereby be used as diagnostics and prognostics for a condition, disorder, or disease involving cell death. Such methods may be used to detect abnormalities in the level of protective sequence expression or of protective sequence product synthesis, or abnormalities in the structure, temporal expression and/or physical location of protective sequence product.
- the antibodies and immunoassay methods described herein have, for example, important in vitro applications in assessing the efficacy of treatments for conditions, disorders, or diseases involving cell death.
- Antibodies, or fragments of antibodies, such as 'those described below, may be used to screen potentially therapeutic compounds in vitro to determine their effects on protective sequence expression and protective sequence product production.
- the compounds which have beneficial effects on conditions, disorders, or diseases involving cell death can thereby be identified, and a therapeutically effective dose determined.
- In vitro immunoassays may also be used, for example, to assess the efficacy of cell-based gene therapy for a condition, disorder, or disease involving cell death.
- Antibodies directed against protective sequence products may be used in vitro to determine, for example, the level of protective sequence expression achieved in cells genetically engineered to produce the protective sequence product. In the case of intracellular protective sequence products, such an assessment is done, preferably, using cell lysates or extracts. Such analysis will allow for a determination of the number of transformed cells necessary to achieve therapeutic efficacy in vivo, as well as optimization of the gene replacement protocol.
- the tissue or cell type to be analyzed generally will include those that are known, or suspected, to express the protective sequence.
- the protein isolation methods employed herein may, for example, be such as those described in Hariow and Lane (1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).
- the isolated cells can be derived from cell culture or from a patient.
- the analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the protective sequence.
- Preferred diagnostic methods for the detection of protective sequence products, conserved variants or peptide fragments thereof may involve, for example, immunoassays wherein the protective sequence products or conserved variants or peptide fragments are detected by their interaction with an anti-protective sequence product-specific antibody.
- antibodies, or fragments of antibodies may be used to, quantitatively or qualitatively, detect the presence of protective sequence products or conserved variants or peptide fragments thereof.
- This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below, this Section) coupled with light microscopic, flow cytometric or fluorimetric detection.
- fluorescently labeled antibody see below, this Section
- flow cytometric or fluorimetric detection are especially preferred for protective sequence products that are expressed on the cell surface.
- the antibodies (or fragments thereof) useful in the present invention may, additionally, be employed histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of protective sequence products, conserved variants or peptide fragments thereof.
- In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody which binds to a protective sequence polypeptide.
- the antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample.
- Immunoassays for protective sequence products will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells or lysates of cells in the presence of a detectably labeled antibody capable of identifying the protective sequence product, conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well- known in the art.
- the biological sample may be brought in contact with and immobilized onto a solid phase support or carrier, such as nitrocellulose, which is capable of immobilizing cells, cell particles or soluble proteins.
- a solid phase support or carrier such as nitrocellulose, which is capable of immobilizing cells, cell particles or soluble proteins.
- the support may then be washed with suitable buffers followed by treatment with the detectably labeled protective sequence product specific antibody.
- the solid phase support may then be washed with the buffer a second time to remove unbound antibody.
- the amount of bound label on the solid support may then be detected by conventional means.
- solid phase support or carrier any support capable of binding an antigen or an antibody.
- supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.
- the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
- the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody.
- the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
- the surface may be flat such as a sheet, test strip, etc.
- Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.
- EIA enzyme immunoassay
- ELISA Enzyme Linked Immunosorbent Assay
- Voller A. et al, 1978, J. Clin. Pathol. 31:507-520; Butler, J.E., 1981, Meth. Enzymol 73:482-523; Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL,; Ishikawa, E. et al, (eds.), 1981, Enzyme Immunoassay, Kgaku Shoin,
- the enzyme that is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means.
- Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, a-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, b-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
- the detection can be accomplished by colorimetric methods that employ a chromogenic substrate for the enzyme. Detection also may be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
- Detection may be accomplished also using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect protective sequence products through the use of a radioimmunoassay
- RIA radioactive isotope
- the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can then be detected due to fluorescence.
- fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
- the antibody can also be detectably labeled using fluorescence emitting metals such as 152 Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTP A) or ethylenediaminetetraacetic acid (EDTA).
- DTP A diethylenetriaminepentacetic acid
- EDTA ethylenediaminetetraacetic acid
- the antibody also can be detectably labeled by coupling it to a chemiluminescent compound.
- the presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
- chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
- Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction.
- bioluminescent protein The presence of a bioluminescent protein is determined by detecting the presence of luminescence.
- Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
- the following assays are designed to identify compounds which bind to a protective sequence product, compounds which bind to proteins, or portions of proteins which interact with a protective sequence product, compounds which modulate, e.g., interfere with, the interaction of a protective sequence product with proteins and compounds which modulate the activity of the protective sequence (i.e., modulate the level of protective sequence expression and/or modulate the level of protective sequence product activity).
- Assays may additionally be utilized which identify compounds which bind to protective sequence regulatory sequences (e.g., promoter sequences; see e.g., Platt, 1994, J. Biol. Chem. 269, 28558-28562), and which can modulate the level of protective sequence expression.
- Such compounds may include, but are not limited to, small organic molecules, such as ones which are able to cross the blood-brain barrier, gain to and/or entry into an appropriate cell and affect expression of the protective sequence or some other gene involved in a protective sequence regulatory pathway.
- Such proteins may be involved in the control and/or regulation of functions related to cell death. Further, among these compounds are compounds which affect the level of protective sequence expression and/or protective sequence product activity and which can be used in the therapeutic treatment of conditions, disorders, or diseases involving cell death as described, below, in Section 5.4.2.3.
- Compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to, Ig-tailed fusion peptides, and members of random peptide libraries; (see, e.g., Lam, et al, 1991, Nature 354:82-84; Houghten, et al, 1991, Nature 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, et al, 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab') 2 and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorgan
- Such compounds may further comprise compounds, in particular drags or members of classes or families of drugs, known to ameliorate the symptoms of a condition, disorder, or disease involving cell death.
- Such compounds include families of antidepressants such as lithium salts, carbamazepine, valproic acid, lysergic acid diethylamide (LSD), -chlorophenylalanine, p- propyldopacetamide dithiocarbamate derivatives e.g., FLA 63; anti-anxiety drugs, e.g., diazepam; monoamine oxidase (MAO) inhibitors, e.g., iproniazid, clorgyline, phenelzine and isocarboxazid; biogenic amine uptake blockers, e.g., tricyclic antidepressants such as desipramine, imipramine and amitriptyline; serotonin reuptake inhibitors e.g., fluoxetine; antipsychotic drugs such as phenothiazine derivatives (e.g., chlorpromazine (thorazine) and trifluopromazine)), but
- In vitro systems may be designed to identify compounds capable of binding the protective sequence products of the invention.
- Compounds identified may be useful, for example, in modulating the activity of unimpaired and/or mutant protective sequence products, may be useful in elaborating the biological function of the protective sequence product, may be utilized in screens for identifying compounds which disrupt normal protective sequence product interactions or may in themselves disrupt such interactions.
- the principle of the assays used to identify compounds which bind to the protective sequence product involves preparing a reaction mixture of the protective sequence product and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways.
- one method to conduct such an assay involves anchoring a protective sequence product or a test substance onto a solid support and detecting protective sequence product/test compound complexes formed on the solid support at the end of the reaction.
- the protective sequence product may be anchored onto a solid support, and the test compound, which is not anchored, may be labeled, either directly or indirectly.
- the anchored component may be immobilized by non-covalent or covalent attachments.
- Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying.
- an immobilized antibody preferably a monoclonal antibody, specific for the protein to be immobilized may be used to anchor the protein to the solid surface.
- the surfaces may be prepared in advance and stored.
- the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface.
- the detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously non- immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously non-immobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).
- a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for the protective sequence product or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.
- Any method suitable for detecting protein-protein interactions may be employed for identifying protective sequence product-protein interactions.
- the amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such proteins. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well known. (See, e.g., Ausubel, supra, and 1990, "PCR Protocols: A Guide to Methods and Applications," Innis, et al, eds. Academic Press, Inc., New York).
- methods may be employed which result in the simultaneous identification of genes that encode a protein that interacts with a protective sequence product. These methods include, for example, probing expression libraries with labeled protective sequence product, using the protective sequence product in a manner similar to the well- known technique of antibody probing of lgtl 1 libraries.
- plasmids are constructed which encode two hybrid proteins: one consists of the DNA-binding domain of a transcription activator protein fused to the protective sequence product and the other consists of the transcription activator protein's activation domain fused to an unknown protein which is encoded by a cDNA which has been recombined into this plasmid as part of a cDNA library.
- the DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast Saccharomyces cerevisiae that contains a reporter gene (e.g., HBS or lacZ) whose regulatory region contains the transcription activator's binding site.
- a reporter gene e.g., HBS or lacZ
- the two-hybrid system or related methodologies may be used to screen activation domain libraries for proteins that interact with the "bait" gene product.
- protective sequence products of the invention may be used as the bait gene product.
- Total genomic or cDNA sequences are fused to the DNA encoding an activation domain.
- This library and a plasmid encoding a hybrid of a bait protective sequence product fused to the DNA-binding domain are co-transformed into a yeast reporter strain, and the resulting transformants are screened for those which express the reporter gene.
- a bait protective sequence such as the open reading frame of the gene
- a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein.
- These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.
- a cDNA library of the cell line, from which proteins which interact with bait protective sequence products are to be detected, can be made using methods routinely practiced in the art. According to the particular system described herein, for example, the cDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4.
- Such a library can be co-transformed along with the bait protective sequence-GAL4 fusion plasmid into a yeast strain that contains a lacZ gene driven by a promoter that contains GAL4 activation sequence.
- a cDNA encoded protein, fused to a GAL4 transcriptional activation domain that interacts with bait protective sequence product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene.
- Colonies that express HIS3 can be detected by their growth on petri dishes containing semi-solid agar based media lacking histidine. The cDNA can then be purified from these strains, and used to produce and isolate the bait protective sequence product-interacting protein using techniques routinely practiced in the art.
- the protective sequence products may, in vivo, interact with one or more macromolecules, including intracellular macromolecules, such as proteins.
- macromolecules may include, but are not limited to, nucleic acid molecules and those proteins identified via methods such as those described, above, in Sections 5.4.2.1 - 5.4.2.2.
- binding partners Compounds that disrupt protective sequence product binding to a binding partner may be useful in regulating the activity of the protective sequence product, especially mutant protective sequence products.
- Such compounds may include, but are not limited to molecules such as peptides, and the like, as described, for example, in Section 5.4.2.1 above.
- the basic principle of an assay system used to identify compounds which interfere with or potentiate the interaction between the protective sequence product and a binding partner or partners involves preparing a reaction mixture containing the protective sequence product and the binding partner under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex.
- the reaction mixture is prepared in the presence and absence of the test compound.
- the test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of protective sequence product and its binding partner. Control reaction mixtures are incubated without the test compound or with a compound that is known not to block complex formation. The formation of any complexes between the protective sequence product and the binding partner is then detected.
- reaction mixtures containing the test compound and normal protective sequence product also may be compared to complex formation within reaction mixtures containing the test compound and a mutant protective sequence product. This comparison may be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal protective sequence product.
- the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of protective sequence product and its binding partner.
- Control reaction mixtures are incubated without the test compound or with a compound that is known not to block complex formation. The formation of any complexes between the protective sequence product and the binding partner is then detected. Increased formation of a complex in the reaction mixture containing the test compound, but not in the control reaction, indicates that the compound enhances and therefore potentiates the interaction of the protective sequence product and the binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal protective sequence product may also be compared to complex formation within reaction mixtures containing the test compound and a mutant protective sequence product. This comparison may be important in those cases wherein it is desirable to identify compounds that enhance interactions of mutant but not normal protective sequence product.
- the above assays may be performed using a reaction mixture containing the protective sequence product, a binding partner and a third compound which disrupts or enhances protective sequence product binding to the binding partner.
- the reaction mixture is prepared and incubated in the presence and absence of the test compound, as described above, and the formation of any complexes between the protective sequence product and the binding partner is detected.
- the formation of a complex in the reaction mixture containing the test compound, but not in the control reaction indicates that the test compound interferes with the ability of the second compound to disrupt protective sequence product binding to its binding partner.
- the assays for compounds that interfere with or potentiate the interaction of the protective sequence products and binding partners can be conducted in a heterogeneous or homogeneous format.
- Heterogeneous assays involve anchoring either the protective sequence product or the binding partner onto a solid support and detecting complexes formed on the solid support at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds which interfere with or potentiate the interaction between the protective sequence products and the binding partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the protective sequence product and interactive intracellular binding partner.
- test compounds which disrupt preformed complexes e.g., compounds with higher binding constants which displace one of the components from the complex
- test compounds which disrupt preformed complexes e.g., compounds with higher binding constants which displace one of the components from the complex
- either the protective sequence product or the interactive binding partner is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly, hi practice, microtiter plates are conveniently utilized.
- the anchored species may be immobilized by non-covalent or covalent attachments. Non- covalent attachment may be accomplished simply by coating the solid surface with a solution of the protective sequence product or binding partner and drying. Alternatively, an immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.
- the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface.
- the detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed.
- an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).
- the antibody in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody.
- test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.
- the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes.
- test compounds which inhibit complex formation or which disrupt preformed complexes can be identified.
- a homogeneous assay can be used.
- a preformed complex of the protective sequence product and the interactive binding partner is prepared in which either the protective sequence product or its binding partners is labeled, but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Patent No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays).
- the addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt protective sequence product/binding partner interaction can be identified.
- these same techniques can be employed using peptide fragments which correspond to the binding domains of the protective sequence product and/or the binding partner (in cases where the binding partner is a protein), in place of one or both of the full length proteins.
- Any number of methods routinely practiced in the art can be used to identify and isolate the binding sites. These methods include, but are not limited to, mutagenesis of the gene encoding one of the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensating mutations in the gene encoding the second species in the complex can then be selected. Sequence analysis of the genes encoding the respective proteins will reveal the mutations that correspond to the region of the protein involved in interactive binding.
- one protein can be anchored to a solid surface using methods described in this Section above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the segments is engineered to express peptide fragments of the protein, it can then be tested for binding activity and purified or synthesized.
- a protective sequence product can be anchored to a solid material as described, above, in this Section by making a GST-1 fusion protein and allowing it to bind to glutathione agarose beads.
- the binding partner can be labeled with a radioactive isotope, such as 35 S, and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-1 fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing the binding partner binding domain, can be eluted, purified and analyzed for amino acid sequence by well-known methods. Peptides so identified can be produced synthetically or produced using recombinant DNA technology.
- Modulate Conditions. Disorders, or Diseases Involving Cell Death Compounds including, but not limited to, binding compounds identified via assay techniques such as those described, above, in Sections 5.4.2.1 - 5.4.2.3, can be tested for the ability to ameliorate symptoms of a condition, disorder, or disease involving cell death.
- the assays described herein can be used to identify compounds which affect activity by either affecting protective sequence expression or by affecting the level of protective sequence product activity.
- compounds may be identified which are involved in another step in the pathway in which the protective .sequence and/or protective sequence product is involved, such as, for example, a step which is either "upstream” or "downstream” of the step in the pathway mediated by the protective sequence.
- Such compounds may, by affecting this same pathway, modulate the effect on the development of conditions, disorders, or diseases involving cell death.
- Such compounds can be used as part of a therapeutic method for the treatment of the condition, disorder, or disease.
- Described below are cell-based and animal model-based assays for the identification of compounds exhibiting such an ability to ameliorate symptoms of a condition, disorder, or disease involving cell death.
- cell-based systems can be used to identify compounds which may act to ameliorate symptoms of a condition, disorder, or disease, including, but not limited to, those described in Section 5.4.1.1.
- Such cell systems can include, for example, recombinant or non-recombinant cell, such as cell lines, which express the protective sequence of interest.
- cells which express the protective sequence of interest may be exposed to a compound suspected of exhibiting an ability to ameliorate symptoms of a condition, disorder, or disease involving cell death at a sufficient concentration and for a sufficient time to elicit such an amelioration of such symptoms in the exposed cells.
- the cells can be assayed to measure alterations in the expression of the protective sequence, e.g., by assaying cell lysates for cerebral mRNA transcripts (e.g., by Northern analysis) or for protective sequence products expressed by the cell; compounds which modulate expression of the protective sequence are good candidates as therapeutics.
- animal-based systems or models for a condition, disorder, or disease involving cell death may be used to identify compounds capable of ameliorating symptoms of the condition, disorder, or disease.
- Such animal models may be used as test substrates for the identification of drags, pharmaceuticals, therapies and interventions.
- animal models may be exposed to a compound suspected of exhibiting an ability to ameliorate symptoms, at a sufficient concentration and for a sufficient time to elicit such an amelioration of symptoms of a condition, disorder, or disease involving cell death. The response of the animals to the exposure may be monitored by assessing the reversal of the symptoms of the condition, disorder, or disease.
- any treatments that reverse any aspect of symptoms of a condition, disorder, or disease involving cell death, should be considered as candidates for human therapeutic intervention in such conditions, disorders, or diseases.
- Dosages of test agents may be determined by deriving dose-response curves, as discussed in
- the polynucleotides of the present invention can be used for various other purposes.
- they can be used to express recombinant protein for analysis, characterization or therapeutic use; as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic conditions, disorders, or diseases; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response.
- the proteins provided by the present invention can similarly be used to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands.
- the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction)
- the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
- the compounds which are determined to affect protective sequence expression or gene product activity can be administered to a patient at therapeutically effective doses to treat or ameliorate a condition, disorder, or disease involving cell death or modulate a cell death-related process described herein.
- a therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of such a condition, disorder, or disease.
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
- Compounds that exhibit large therapeutic indices are preferred. While compounds which exhibit toxic side effects may be used, care should be taken to design a delivery system which targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range which includes the IC 50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
- a therapeutically effective amount of antibody, protein, or polypeptide ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
- treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.
- a subject is treated with antibody, protein, or polypeptide in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks.
- the effective dosage of antibody, protein, or polypeptide used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.
- compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.
- the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral rectal or topical administration.
- the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
- binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl- p-hydroxybenzoates or sorbic acid).
- the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- compositions of the invention may be desirable to administer locally to the area in need of treatment.
- This may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
- administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.
- the compounds may be combined with a carrier so that an effective dosage is delivered, based on the desired activity.
- the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- a human fetal brain cDNA library (Gibco), in which individual clones were inserted into the Notl-Sall site of the pCMVSPORT2 vector, was diluted 200,000 fold in LB broth (DIFCO Laboratories) containing 0.2 mg/ml ampicillin (Sigma).
- the diluted library was diluted 200,000 fold in LB broth (DIFCO Laboratories) containing 0.2 mg/ml ampicillin (Sigma).
- Remaining bacterial cells were centrifuged at 1000 x g for 6 minutes to collect the cells at the bottom. Following centrifugation, the broth was decanted off of the bacterial pellet and the pellet resuspended and then stored in 100 ⁇ l of Cell Resuspension Solution (Promega) at 4°C for up to one week.
- Plasmid DNA was extracted using Promega MagneSil kits with a modified protocol. The pelleted bacteria were re-suspended and 50 ⁇ l was transferred into a round bottom plate that rests on a magnet. Cell Lysis Solution (50 ⁇ l) was added and the plate was incubated at room temperature without agitation for 30 seconds. Following lysis, 70 ⁇ l of a Neutralization Solution/MagneSil Paramagnetic Particles mixture (pre-mixed at a ratio of 6:1) was added. The reaction was mixed by pipetting and incubated at room temperature without agitation for 5 minutes to allow the magnetic particles to be drawn to the magnet.
- a Neutralization Solution/MagneSil Paramagnetic Particles mixture pre-mixed at a ratio of 6:1
- the supernatant containing plasmid DNA was then transferred to a new plate and stored at -20°C.
- the cDNA inserts of the clonally pure plasmids which are selected for their ability to protect cells from cell death when introduced into cells predisposed to undergo cell death are sequenced using the ABI Big Dye terminator Cycle Sequencing Ready Reaction Kit and subsequently analyzed on the ABI310 capillary sequencing machine (PE Biosystems, Foster City, CA).
- plasmid DNA is mixed with 3.2 pmole of either the M13 forward (5'- TGTAAAACGACGGCCAGT-3'; SEQ ID NO:465) or the M13 reverse (5'-CAGGAAACAGCTATGACC-3'; SEQ ID NO:466) sequencing primer and 8 ml of the terminator ready reaction mix in a total volume of 20 ml.
- the cycle sequencing reaction is carried out in a thermocycler (PCR machine) using standard methods known by those skilled in the art.
- the extension products from the sequencing reaction are purified by precipitation using isopropanol. 80 ml of 75% isopropanol is added to the sample and after thorough mixing, the sample is incubated at room temperature (25°C) for 20 minutes.
- the sample is then centrifuged at 12,000 x g for 20 minutes at room temperature. The supernatant is removed and the pellet is rinsed once by addition of 250 ml of 75% isopropanol followed by centrifugation as above for 5 minutes. The supernatant is removed and the sample air-dried for 10 minutes. The sample is then resuspended in 20 ml of TSR (template suppression reagent) and denatured by heating at 94°C for 2 minutes and rapidly cooling on ice. The subsequent electrophoresis and analysis is carried out on the ABI310 sequencer according to the manufacturer's protocol. The entire cDNA clone is similarly sequenced by the use of sequence specific internal primers as required.
- TSR template suppression reagent
- BLAST 2.0 algorithm Altschul, SF et al, 1997, Nuc. Acids Res. 25:3389
- This program uses the two-hit method to find homology within the database.
- Transfected tissue is immersed in freshly prepared 2.5% paraformaldehyde
- PFA phosphate buffered saline
- PBS phosphate buffered saline
- the tissue After removal of the blocking solution, the tissue is immersed in a primary antibody solution, freshly prepared by adding rabbit anti-GFP polyclonal (1:2000 ul) into blocking solution, for an incubation period of twelve hours at 4°C.
- the tissue After removal of the primary antibody solution, the tissue is washed consecutively four times in PBS for 10 minutes, changing the PBS solution between each wash.
- An anti-rabbit, flourescently conjugated secondary antibody diluted in PBS at a concentration of 1:500, is then added to the tissue and allowed to incubate at room temperature for four hours.
- the secondary antibody solution is removed by aspiration and the tissue washed consecutively four times in PBS for 15 minutes, changing the PBS solution between each wash.
- the tissue After the final wash is removed, the tissue is mounted on glass slides and dried at 37°C for thirty minutes. A three-minute xylene incubation is performed before the addition of coverslips to preserve the slices.
- Protective sequence CNI-00733 (SEQ. ED NO:l) comprises
- CNI-00733 caused about a 10-fold increase in the number of surviving neurons in stroked rat cortical brain slices compared to negative control slices which were exposed to EGFP with no protective sequence.
- Protective sequence CNI-00736 (SEQ. ID NO:32) comprises
- GenBank database reveals a 99.7% identity (1138/1141 bases) with the human mitochondrial sequence encoding the 16S ribosomal RNA (ACC No. V00710).
- CNI-00736 caused about a 19-fold increase in the number of surviving neurons in stroked rat cortical brain slices compared to negative control slices which were exposed to EGFP with no protective sequence.
- Protective sequence CNI-00738 (SEQ. ID NO:57) comprises
- KIAA0370 (ACC No. AB002368).
- CNI-00738 is 100% identical with the 1-748 amino acid region of the KIAA0370 protein.
- the KIAA0370 protein is an unidentified brain protein.
- CNI-00738 caused about a 12-fold increase in the number of surviving neurons in stroked rat cortical brain slices compared to negative control slices which were exposed to EGFP with no protective sequence.
- Protective sequence CNI-00742 (SEQ. ID NO: 166) comprises
- CNI-00734 BLAST sequence comparison analysis of CNI-00734 against known nucleic acids in the GenBank database reveals a 99% identity (878/883 bases) with the human mitochondrial sequence encoding the 16S ribosomal RNA (ACC No. V00710).
- CNI-00742 caused about a 12-fold increase in the number of surviving neurons in stroked rat cortical brain slices compared to negative control slices which were exposed to EGFP with no protective sequence.
- Protective sequence CNI-00748 (SEQ. ID NO:219) is a completely novel sequence which comprises 2377 nucleotides. Twenty-four (24) potential ORFs have been identified within the protective sequence and are depicted in Table 6. The longest ORF is 106 amino acids.
- BLAST sequence comparison analysis of CNI-00748 against known nucleotide and protein sequences in the GenBank database reveals no significant homology at either the nucleotide or the amino acid level. As shown in Figure 3F, CNI-00748 caused about a 28-fold increase in the number of surviving neurons in stroked rat cortical brain slices compared to negative control slices which were exposed to EGFP with no protective sequence.
- CNI-NPP5-CP5 represents a composite deposit of a mixture of ten (10) DNA clones.
- a sample of the DNA preparation can be digested with Not I and Sal I, and the resulting products can be separated by standard gel electrophoresis. techniques using a 1% agarose gel in TAE buffer. Liberated inserts are of the following approximate sizes:
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001256998A AU2001256998A1 (en) | 2000-04-11 | 2001-04-09 | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54793800A | 2000-04-11 | 2000-04-11 | |
US09/547,938 | 2000-04-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001081361A1 true WO2001081361A1 (en) | 2001-11-01 |
WO2001081361A8 WO2001081361A8 (en) | 2002-02-28 |
WO2001081361B1 WO2001081361B1 (en) | 2002-06-27 |
Family
ID=24186756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011501 WO2001081361A1 (en) | 2000-04-11 | 2001-04-09 | Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001256998A1 (en) |
WO (1) | WO2001081361A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097687A2 (en) * | 2002-05-16 | 2003-11-27 | Ikuo Nishimoto | Neuroprotective polypeptides and methods of use |
WO2009040017A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
US8309525B2 (en) | 2007-05-30 | 2012-11-13 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
US8637470B2 (en) | 2008-05-01 | 2014-01-28 | The Regents Of The University Of California | Small humanin-like peptides |
WO2021030792A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
WO2021030799A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
WO2021030749A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016178A2 (en) * | 1992-02-12 | 1993-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sequences characteristic of human gene transcription product |
-
2001
- 2001-04-09 WO PCT/US2001/011501 patent/WO2001081361A1/en active Application Filing
- 2001-04-09 AU AU2001256998A patent/AU2001256998A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016178A2 (en) * | 1992-02-12 | 1993-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sequences characteristic of human gene transcription product |
Non-Patent Citations (9)
Title |
---|
AM. J. MED. GENET, vol. 74, no. 2, 1997, pages 140 - 149 * |
DATABASE GENBANK [online] 1 February 2001 (2001-02-01), ANDERSON ET AL.: "Sequence and organization of the human mitochondrial genome", XP002942652, Database accession no. AB055387 * |
DATABASE GENBANK [online] 13 February 1999 (1999-02-13), NAGASE ET AL.: "Direct submission", XP002942650, Database accession no. AB002368 * |
DATABASE GENBANK [online] 16 March 1994 (1994-03-16), ADAMS ET AL.: "Human brain expressed sequence tag EST02017", XP002942649, Database accession no. AAQ60035 * |
DATABASE GENBANK [online] 17 February 1998 (1998-02-17), YOSHIKAWA ET AL.: "Isolation of chromosome 18-specific brain transcripts as positional candidates for bipolar disorder", XP002942653, Database accession no. AF009427 * |
DATABASE GENBANK [online] HECKEL ET AL.: "Novel immunogenic antigen homologous to hyaluronidase in meningioma", XP002942651, Database accession no. AF036145 * |
DNA RESEARCH, vol. 4, no. 2, 1997, pages 140 - 150 * |
HUM. MOL. GENET., vol. 7, no. 12, 1998, pages 1859 - 1872 * |
NATURE, vol. 290, no. 5806, pages 457 - 465 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097687A2 (en) * | 2002-05-16 | 2003-11-27 | Ikuo Nishimoto | Neuroprotective polypeptides and methods of use |
WO2003097687A3 (en) * | 2002-05-16 | 2004-07-08 | Ikuo Nishimoto | Neuroprotective polypeptides and methods of use |
US8309525B2 (en) | 2007-05-30 | 2012-11-13 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
US9034825B2 (en) | 2007-05-30 | 2015-05-19 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of myocardial injury with humanin analogs |
WO2009040017A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009040017A3 (en) * | 2007-09-11 | 2009-09-03 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
US8637470B2 (en) | 2008-05-01 | 2014-01-28 | The Regents Of The University Of California | Small humanin-like peptides |
WO2021030792A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
WO2021030799A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
WO2021030749A1 (en) * | 2019-08-15 | 2021-02-18 | Cohbar, Inc. | Therapeutic peptides |
Also Published As
Publication number | Publication date |
---|---|
WO2001081361B1 (en) | 2002-06-27 |
WO2001081361A8 (en) | 2002-02-28 |
AU2001256998A1 (en) | 2001-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6277974B1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
WO2001076532A9 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
WO2001081361A1 (en) | Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death | |
WO2001076457A2 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
US5866412A (en) | Chromosome 18 marker | |
AU754436B2 (en) | Methods and compositions for diagnosing and treating chromosome-18p related disorders | |
EP1098977A2 (en) | Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity | |
US5955355A (en) | Chromosome 18 marker | |
JP2001503631A (en) | Glaucoma-associated proteins and corresponding nucleic acids and their use in therapy and diagnosis | |
WO1998042362A9 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
AU780591B2 (en) | Novel human ion channel proteins | |
WO2003006479A1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
US5914394A (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
US5939316A (en) | Chromosome 18 marker | |
CA2298474A1 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
WO1998042723A9 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
US6548271B1 (en) | Nucleic acids encoding human transporter proteins | |
WO2000053630A2 (en) | COMPOUNDS THAT DISRUPT MAMMALIAN Rad51 ACTIVITY | |
AU5118399A (en) | Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity | |
WO2001034773A2 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS | |
MXPA00008949A (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS | |
MXPA00009702A (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WR | Later publication of a revised version of an international search report | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED:03.02.03) |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |